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BIS-PYRIDINO CONTAINING COMPOUNDS
FOR THE USE IN THE TREATMENT OF CNS
PATHOLOGIES

cycloalkyl, pyrrolidine; N-alkyl pyrrolidine, Where the alkyl
chain is methyl, ethyl or propyl; unsaturated pyrrolidine;
unsaturated N-alkyl pyrrolidine, Where the alkyl chain is
methyl, ethyl or propyl; aZiridine; N-methyl aZiridine; aZeti
dine; N-methyl aZetidine; unsaturated aZetidine; unsaturated

RELATED APPLICATIONS

N-methyl aZetidine; piperidine; N-methyl piperidine; unsat

This application is a Divisional of US. application Ser. No.

urated piperidine; unsaturated N-methyl piperidine; aZepane;

12/219,190, ?led on Jul. 17, 2008 noW abandoned, Which is a

N-methyl aZepane; unsaturated aZepane; unsaturated N-me
thyl aZepane; aZocane; N-methyl aZocane; unsaturated aZo
cane; unsaturated N-methyl aZocane; 1-aZa-bicyclo[3.2.1]

Divisional ofU.S. application Ser. No. 11/027,675, ?led Jan.
3, 2005 noW abandoned, Which claims priority to US. Pro
visional Application Ser. No. 60/533,213, ?led Dec. 31, 2003,
Which is incorporated herein in its entirety.

octane;

BACKGROUND OF THE INVENTION

neuronal nicotinic receptor (nAChR) agonists as therapeutic
agents. HoWever, relatively feW studies have focused on the

therapeutic development of nAChR antagonists. As a result,
only a feW subtype-selective antagonists are currently avail

aZiridine; methyl aZetidine; methyl N-methyl aZetidine;
20

It has been found that nicotine stimulates all knoWn nAChR

methyl unsaturated piperidine; methyl unsaturated N-methyl
piperidine; methyl aZepane; methyl N-methyl aZepane;
methyl unsaturated aZepane; methyl unsaturated N-methyl

subtypes, and that N-quatemiZation of nicotine converts it
from an agonist into an antagonist With enhanced nAChR

subtype selectivity. Several classical nAChR antagonists are

ride and decamethonium bromide, both bis-quaternary
ammonium salts, are considered simpli?ed analogs of d-tub
ocurarine. The latter drugs have been used to distinguish
betWeen peripheral nAChR subtypes, speci?cally neuromus
cular and ganglionic nAChRs. More recently, quaternary
ammonium N-n-alkyl analogs of nicotine have been reported
to be nAChR subtype-selective antagonists. HoWever, it is
generally believed that quaternary ammonium compounds do
not easily access the brain due to their charge and polarity.
Thus, there remains a need for compounds that are bioavail
able in the brain and effective in treatment of nicotine addic
tion and dopamine mediated disease states.

25

methyl 1-aZa-bicyclo[3.2.1]octane; methyl 1-aZa-bicyclo
[2 .2. 1]heptane;
30

R1 is selected from alkyl, substituted alkyl, cycloalkyl,

substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, arylalkyl, substi
tuted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalky
35

nyl, substituted arylalkynyl, heterocyclic, substituted hetero

cyclic, alkoxy, alkylamine, thioalkyl; and
X is selected from Cl, Br, I, HSO4, 1/2SO2, CH3SO3, p-TsO,

40

cation of the nicotine molecule by (1) quaterniZation of the

CF3SO3 and any ion that completes the salt form of the nico
tine antagonist; and enantomers, diastereomers and racemic
mixes thereof.
The nicotine antagonists of the invention are useful for the
treatment of dopamine related conditions and dopamine-me
diated disease states such as myasthenia gravis, Parkinson’s

disease, AlZheimer’s disease, schizophrenia, eating disor
45

N-substituted analogs, and (2) modifying the structure of the

ders, and drug addiction. These compounds are also useful
When used as substitutes for psycho-stimulant self-adminis
tration. The nicotine antagonists of the invention are particu

nicotinium cationic head group. The compounds of the inven
tion are nicotine antagonists having the formula

larly useful for treating drug addiction due to nicotinic ago
50

55

60

R2, R3, R4, R5, R6 are each independently selected from
hydrogen; alkyl; substituted alkyl; cycloalkyl; substituted

8-methyl-8-aZa-bicyclo[3 .2 . 1 ]octane;

methyl 1-aZa-tricyclo[3.3 .1 .1]decane;

The present invention is directed to the development and
therapeutic use of nAChR subtype-selective and brain-bio
available antagonists. The compounds are made via modi?

Wherein:

aZepane; methyl aZocane; methyl N-methyl aZocane; methyl
unsaturated aZocane; methyl unsaturated N-methyl aZocane;

BRIEF SUMMARY OF THE INVENTION

pyridine-N atom With a lipophillic substituent to afford

methyl unsaturated aZetidine; methyl unsaturated N-methyl

aZetidine; methyl piperidine; methyl N-methyl piperidine;

ological roles of speci?c nAChR subtypes.

bis-quaternary ammonium structures. Hexamethonium chlo

8-methyl-8-aZa

methyl N-alkyl pyrrolidine, Where the alkyl chain is methyl,
ethyl or propyl; methyl unsaturated pyrrolidine; methyl
unsaturated N-alkyl pyrrolidine, Where the alkyl chain is
methyl, ethyl or propyl; methyl aZiridine; methyl N-methyl

Considerable effort has focused on the development of

able for use as pharmacological tools to investigate the physi

1-aZa-bicyclo [2 .2. 1]heptane;

bicyclo[3.2.1]octane; 1-aZa-tricyclo[3.3.1.1]decane; methyl
cycloalkyl; methyl substituted cycloalkyl, methylpyrrolidine;

65

nists, cocaine, amphetamines, caffeine, phencyclidine,
opiates, barbituates, benZodiaZepines, cannabinoids, halluci
nogens and alcohol.
The invention further includes a method of treating nico
tine addiction by administering a formulation containing one
or more compounds of the invention to the patient. The com

pounds and compositions of the invention may be adminis
tered by applying the formulation to a medical patch Which is
then attached or adhered to the skin of the patient; providing
an oral formulation Which is taken orally; providing a formu
lation Which is injected into the patient With a syringe or
similar device; providing a formulation Which is applied to
the nasal cavity; providing a formulation Which is applied to

the rectum; providing a formulation Which is inhaled; provid
ing a formulation Which is applied sublingual; and any other
means of applying the formulation to the patient.
In another aspect of the invention the nicotine antagonists
of the invention are administered to a patient in order to

US 8,546,415 B2
4
aZiridine; methyl aZetidine; methyl N-methyl aZetidine;

3
inhibit dopamine release from presynaptic terminals in neu
ronal dopamine tissue in a stereoselective and receptor-me

methyl unsaturated aZetidine; methyl unsaturated N-methyl

aZetidine; methyl piperidine; methyl N-methyl piperidine;

diated manner.

methyl unsaturated piperidine; methyl unsaturated N-methyl
piperidine; methyl aZepane; methyl N-methyl aZepane;
methyl unsaturated aZepane; methyl unsaturated N-methyl

BRIEF DESCRIPTION OF THE DRAWINGS

aZepane; methyl aZocane; methyl N-methyl aZocane; methyl

FIG. 1 shows the general chemical structure of the bis-alkyl
pyridino compounds of the invention. The identities of R and

unsaturated aZocane; methyl unsaturated N-methyl aZocane;

X groups are described herein.

methyl 1-aZa-bicyclo[3.2.1]octane; methyl 1-aZa-bicyclo
[2 .2. 1]heptane;

FIG. 2 shoWs the structures of ?ve series of bis-aZaaro

R1 is selected from but not limited to, alkyl, substituted

alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
arylalkyl, substituted arylalkyl, arylalkenyl, substituted ary
lalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic,
substituted heterocyclic, alkoxy, alkylamine, thioalkyl; and
X is selected from Cl, Br, I, HSO4, 1/2SO2, CH3SO3, p-TsO

FIG. 3 shoWs the chemical structures of N-n-alkylnico

tinium (1-3), N-n-alkylpyridinium (4-7), and conforrnation
ally restricted N-n-alkylnicotinium (8-17) iodides and bro
mides.
FIG. 4 shoWs the chemical structures of N,N'-dode

canediyl-bis-nicotinium dibromide (18, bNDDB) and N,N'
dodecanediyl-bis-pyridinium dibromide (19, bPDDB).
FIG. 5 shoWs the chemical structures of the analogs of

8-methyl-8-aZa-bicyclo[3 .2 . 1 ]octane;

methyl 1-aZa-tricyclo[3.3 .1 .13’7]decane.

matic analogs differentiated by their head groups. The abbre
viated nomenclature is given in parentheses.

or CF3SO3, or any other ion Which Would complete the salt
20

form of the compound.

N-n-alkylpicolinium (on the left) and N,N'-alkyl-bis-pi
colinium (on the right).

of R groups (i.e., R2R3, R3R4, R4R5, R5R6) represent a fused

DETAILED DESCRIPTION OF THE INVENTION

limited to, (CH2) Where n:3-8, benZene, pyridine, pyran,

In one embodiment of the present invention, combinations

aromatic or unsaturated ring Z, Where Z includes, but is not
25

During the development of nAChR receptor antagonists,
We discovered that structural modi?cation of the nicotine
molecule converted nicotine into a series of N-n-alkylnico

tinium analogs exhibiting antagonist activity at speci?c
nAChR subtypes, and several of these antagonists shoWed

30

both high a?inity and subtype-selectivity (Table 4). N-n
Alkylation of nicotine converts nicotine from an agonist into
an antagonist at neuronal nicotinic acetylcholine receptor

subtypes mediating nicotine-evoked dopamine release. Con
formationally restricted analogs exhibit both high a?inity and

35

selectivity at this site, and are able to access the brain due to
their ability to act as substrates for the blood-brain barrier

choline transporter.
Furthermore, When the pyridine-N atom of nicotine is
n-alkylated With chain lengths 2C6, no intrinsic activity at
native nAChRs in dopamine release and 86Rb+ ef?ux assays is
ob served. Moreover, nicotine-evoked dopamine release from
striatal slices and nicotine-evoked 86Rb+ ef?ux from thalamic
synaptosomes (a functional assay for the (x4[32* receptor) is

inhibited by these analogs.

decahydro-quinoline including all possible substitution
patterns, geometric and stereoisomers, racemic, diastereo
40

In certain compounds of the invention, ring 1 and ring 2 are

cycle including, but not limited to, pyrrole, pyrrolidine, pyra

Zole, imidaZole, 1,2,3-triaZole, 1,2,4-triaZole, pyridine,

The compounds of the present invention are bis-alkyl pyri
dino compounds corresponding to the chemical structure
shoWn in FIG. 1 (Formula I), Wherein:

N-methyl aZepane; unsaturated aZepane; unsaturated N-me
thyl aZepane; aZocane; N-methyl aZocane; unsaturated aZo
cane; unsaturated N-methyl aZocane; 1-aZa-bicyclo[3.2.1]

octane;

1-aZa-bicyclo[2.2.1]heptane;

bicyclo [3 .2.1]octane;

50

from the group consisting of hydrogen, halogen, alkyl or
alkanoyl; R3 is individually selected from the group consist

ing of hydrogen, halogen, alkyl, alkanoyl, amino, alkylamino,
piperidine, N-methyl piperidine, pyrrolidine, N-methylpyr
rolidine or quinuclidine; R1 is a branched or non-branched
C4-C 19 alkyl; and X is iodine or bromine.
55

N,N'-alkyl-bis-picolinium analogs and other bis-aZaaro
matic analogs Were synthesiZed and assessed in nicotinic

receptor (nAChR) assays. Preferred bis-aZaaromatic analogs
have 6-12 carbon atoms in the alkyl chain, With an even

number of carbon atoms in the alkyl chain being preferred to
60

8-methyl-8-aZa

an odd number of carbon atoms, and a longer chain being
preferred to a shorter chain. The most potent and subtype

selective analog, N,N'-dodecyl-bis-picolinium bromide
(bPiDDB), inhibited nAChRs mediating nicotine-evoked
[3H]dopamine release (ICSOIS nM; Imax of 60%), and did not

1-aZa-tricyclo [3 .3 .1 . 13’7]decane;

methyl cycloalkyl; methyl substituted cycloalkyl, methylpyr
rolidine; methyl N-alkyl pyrrolidine, Where the alkyl chain is
methyl, ethyl or propyl; methyl unsaturated pyrrolidine;
methyl unsaturated N-alkyl pyrrolidine, Where the alkyl chain
is methyl, ethyl or propyl; methyl aZiridine; methyl N-methyl

pyridaZine, pyrimidine, pyraZine, or triaZine, including all
possible substitution patterns, geometric and stereoisomers,
racemic, diastereomeric and enantiomeric forms thereof.
It is preferred that R2, R4, R5 , R6, are individually selected

chain is methyl, ethyl or propyl; unsaturated pyrrolidine;
unsaturated N-alkyl pyrrolidine, Where the alkyl chain is

methyl, ethyl or propyl; aZiridine; N-methyl aZiridine; aZeti
dine; N-methyl aZetidine; unsaturated aZetidine; unsaturated
N-methyl aZetidine; piperidine; N-methyl piperidine; unsat
urated piperidine; unsaturated N-methyl piperidine; aZepane;

meric and enantiomeric forms thereof.
identical or independently an unsaturated nitrogen hetero

45

R2, R3, R4, R5, R6 are each independently selected from
hydrogen; alkyl; substituted alkyl; cycloalkyl; substituted
cycloalkyl, pyrrolidine; N-alkyl pyrrolidine, Where the alkyl

indene, isoindene, benZofuran, isobenZofuran, benZo [b]
thiophene, benZo[c]thiophene, indole, indolenine, isoindole,
cyclopental[b]pyridine, pyrano[3,4-b]pyrrole, indaZole,
indoXaZine, benZosaZole, anthranil, naphthalene, tetralin,
decalin, chromene, coumarin, chroman-4-one, isocoumarin,
isochromen-3-one, quinoline, isoquinoline, cinnoline,
quinaZoline, naphthyridine, pyrido[3,4-b]-pyridine, pyridol
[3,2-b]pyridine, pyrido[4,3,-b]-pyridine, benZoxaZine,
anthracene, phenanthrene, phenalene, ?uorene, caraZole,
Xanthene, acridine, octahydro-[1]pyridine, 1-methyl octahy
dro-[1]pyridine, octahydro-indole, 1-methyl octahydro-in
dole, octahydro-cyclopenta[b]pyrrole, lmethyl-octahydro
cyclopenta[b]pyrrole, decahydro-quinoline, 1-methyl

65

interact With (x4[32* or 0L7* nAChRs. Therefore, bPiDDB is
the most preferred compound for use as a tobacco use cessa

tion agent and for inhibiting release of dopamine.

US 8,546,415 B2
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5
The invention includes but is not limited to the use of

“halogen” refers to ?uoride, chloride, bromide or iodide

compounds having the structures shoWn in FIGS. 1-5, Which
Were prepared by quaterniZing the pyridinic nitrogen atom of

radicals; and

nicotine With a lipophillic substituent group and modifying

pounds of the invention, refers to doses of compound su?i
cient to provide circulating concentrations high enough to

an “effective amount”, When used in reference to com

the structure of the nicotinium cationic head group.

The invention also includes compositions comprising one

impart a bene?cial effect on the recipient thereof. Such levels

or more of the chemical compounds shoWn in FIGS. 1-5 for
use as a tobacco use cessation agent. The most preferred

typically fall in the range of about 0.001 up to 100 mg/kg/ day;
With levels in the range of about 0.05 up to 10 mg/kg/day

compound for this purpose is N,N'-dodecyl-bis-picolinium

being preferred.
The compounds of the invention exhibit various degrees of

bromide (bPiDDB), shoWn in FIG. 5.
As employed herein, the aforementioned terms are de?ned

inhibition of dopamine release from a subset of nicotine
receptors. In one embodiment of the invention, a nicotine
antagonist of the invention or combination of nicotine antago
nisits is administered to a patient in order to inhibit dopamine

as folloWs:

“loWer alkyl” refers to straight or branched chain alkyl
radicals having in the range of about 1 up to 4 carbon atoms;
“alkyl” refers to straight or branched chain alkyl radicals
having in the range of about 1 up to 19 carbon atoms unless
otherWise speci?ed, preferably 1-12 carbon atoms, and more
preferably 6-12 carbon atoms, and most preferably 9-12 car

5

sue in a stereoselective and receptor-mediated manner. The

compounds are also able to pass through the blood-brain
barrier by accessing the blood-brain barrier choline trans
porter. Thus, the compounds of the invention are useful in the

bon atoms; and “substituted alkyl” refers to alkyl radicals
further bearing one or more substituents such as hydroxy,

20

alkoxy (of a loWer alkyl group), mercapto (of a loWer alkyl

group), aryl, heterocyclic, halogen, tri?uoromethyl, cyano,
nitro, amino, carboxyl, carbamate, sulfonyl, sulfonamide,
25

taining in the range of about 3 up to 8 carbon atoms and

“substituted cycloalkyl” refers to cycloalkyl radicals further
bearing one or more substituent as set forth above;

“alkenyl” refers to straight or branched chain hydrocarbyl
radicals having at least one carbon-carbon double bond, and
having in the range of about 2 up to 19 carbon atoms, prefer
ably 2 to 12 carbon atoms, and more preferably 6 to 12 carbon
atoms, and most preferably 9-12 carbon atoms; and “substi
tuted alkenyl” refers to alkenyl radicals further bearing one or
more substituents as set forth above;

30

35

(bPiUB),
40

“aryl” refers to aromatic radicals having in the range of
aryl radicals further bearing one or more substituents as set 45

forth above;
“alkylaryl” refers to alkyl-substituted aryl radicals and
“substituted alkylaryl” refers to alkylaryl radicals further

(bQDDB),

N,N'-Hexane-1,6-diyl-bis-isoquinolinium;

“arylalkenyl” refers to aryl-substituted alkenyl radicals

Diiodide

(blQHxl),
(bIQNB),

N,N'-Decane-1,10-diyl-bis-isoquinolinium;

and “substituted arylalkenyl” refers to arylalkenyl radicals
55

“arylalkynyl” refers to aryl-substituted alkynyl radicals

Diiodide

(bIQDI).
N,N'-Undecane-1, 1'-diyl-bis-isoquinolinium;

and “substituted arylalkynyl” refers to arylalkynyl radicals

Dibromide

(bIQUB),
N,N'-Dodecane-1,12-diyl-bis-isoquinolinium;

further bearing one or more substituents as set forth above;

Dibromide

(bIQDDB),
60

one or more substituents as set forth above;

“heterocyclic” refers to cyclic radicals containing one or
more heteroatoms as part of the ring structure, and having in

carbonyl species;

Dibromide

N,N'-Octane-1,8-diyl-bis-isoquinolinium; Diiodide (blQOl),
N,N'-Nonane-1 ,9-diyl-bis-isoquinolinium;
Dibromide

bearing one or more substituents as set forth above;

the range of 3 up to 24 carbon atoms and “substituted hetero
cyclic” refers to heterocyclic radicals further bearing one or
more substituents as set forth above; “acyl” refers to alkyl

N,N'-Hexane-1,6-diyl-bis-quinolinium; Diiodide (bQHXl),
N,N'-Octane-1,8-diyl-bis-quinolinium; Diiodide (bQOl),
N,N'-Nonane-1,9-diyl-bis-quinolinium; Dibromide (bQNB),
N,N'-Decane-1,10-diyl-bis-quinolinium; Diiodide (bQDl),
N,N'-Undecane-1, 1'-diyl-bis-quinolinium;
Dibromide

(bQUB),

50

Dibromide

(bPiDDB),

N,N'-Dodecane-1,12-diyl-bis-quinolinium;

bearing one or more substituents as set forth above;

“aroyl” refers to aryl-substituted species such as benZoyl
and “substituted aroyl” refers to aroyl radicals further bearing

N,N'-Hexane-1,6-diyl-bis-picolinium; Diiodide (bPiHXl),
N,N'-Octane-1,8-diyl-bis-picolinium; Diiodide (bPiOl),
N,N'-Nonane-1,9-diyl-bis-picolinium; Dibromide (bPiNB),
N,N'-Decane-1,10-diyl-bis-picolinium; Diiodide (bPiDl),
N,N'-Undecane-1,1'-diyl-bis-picolinium;
Dibromide
N,N'-Dodecane-1,12-diyl-bis-picolinium;

about 6 to 24 carbon atoms and “substituted aryl” refers to

further bearing one or more substituents as set forth above;

(bPUB),

DDB),

more substituents as set forth above;

“arylalkyl” refers to aryl-substituted alkyl radicals and
“substituted arylalkyl” refers to arylalkyl radicals further

N,N'-Pentane-1,5-diyl-bis-pyridinium; Diiodide (bPPel),
N,N'-Hexane-1,6-diyl-bis-pyridinium; Diiodide (bPHxl),
N,N'-Octane-1,8-diyl-bis-pyridinium; Diiodide (bPOl),
N,N'-Nonane-1,9-diyl-bis-pyridinium; Dibromide (bPNB),
N,N'-Decane-1,10-diyl-bis-pyridinium; Diiodide (bPDl),
N,N'-Undecane-1, 1'-diyl-bis-pyridinium;
Dibromide
N,N'-Dodecane-1,12-diyl-bis-pyridinium; Dibromide (bP

“alkynyl” refers to straight or branched chain hydrocarbyl
radicals having at least one carbon-carbon triple bond, and
having in the range of about 2 up to 19 carbon atoms, prefer
ably 2 to 12 carbon atoms, and more preferably 6 to 12 carbon
atoms, and most preferably 9-12 carbon atoms; and “substi
tuted alkynyl” refers to alkynyl radicals further bearing one or

treatment of smoking addiction and other dopamine-medi
ated conditions and diseases. Preferred compounds in the
treatment of smoking addiction and dopamine-mediated con
ditions and diseases include:

and the like.

“Cycloalkyl” refers to cyclic ring-containing radicals con

release from presynaptic terminals in neuronal dopamine tis

65

N,N'-Hexane-1,6-diyl-bis-nicotinium; Diiodide (bNHXl),
N,N'-Octane-1,8-diyl-bis-nicotinium; Diiodide (bNOl),
N,N'-Nonane-1,9-diyl-bis-nicotinium; Dibromide (bNNB),
N,N'-Decane-1,10-diyl-bis-nicotinium; Diiodide (bNDl),
N,N'-Undecane-1,1'-diyl-bis-nicotinium;
Dibromide

(bNUB),

N,N'-Dodecane-1,12-diyl-bis-nicotinium;

(bNDDB).

Dibromide

US 8,546,415 B2
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The compounds of the invention can be prepared from
corresponding free bases by reaction With an appropriate
alkyl iodide using techniques knoWn to those skilled in the art

cantly larger molecular Weight than nicotine, and the steri
cally bulky N-n-alkyl chain may interact Within a hydropho
bic cavity extending outside the normal volume for agonist
binding to the receptor. N-n-Alkylnicotinium analogs have

of organic synthesis.

been proposed to interact With the nAChR mediating nico

The nicotine antagonists of Formula I include all possible
diastereomers and all enantiomeric forms as Well as racemic

tine-evoked dopamine release in the unprotonated form, lead

mixtures. The compounds can be separated into substantially
optically pure compounds. The compounds of the invention
are nicotinic receptor agents, Which inhibit [3H]nicotine

ing moieties. Thus, the quaternary pyridinium N-atom of the

ing to a reversal in the role of the pharmacophoric N-contain

antagonist molecule is believed to interact With the binding

site that normally accommodates the protonated pyrrolidine
N-atom in the agonist binding mode, and the unprotonated
pyrrolidine N-atom of the antagonist molecule substitutes for
the pyridine N-atom of the agonist molecule at the hydrogen
bonding site of the nAChR. Alternatively, these N-n-alkylni

binding and [3 H] MLA binding and nicotine-evoked [3 H] DA
release from a subset of nACh receptors that mediate nico

tine-evoked dopamine release. Thus, the compounds of the
invention are useful in treatment of dopamine mediated dis

eases, such as myasthenia gravis, Parkinson’s disease, AlZhe

imer’s disease, schizophrenia, eating disorders, and drug

cotinium molecules may interact With the nicotine binding
site in a manner alloWing free positioning of the n-alkyl chain

addiction. The compounds may also be used as substitutes for

into the receptor ion channel, thereby sterically inhibiting ion

psycho-stimulant self-administration.
The nicotine antagonists of the invention can be adminis
tered in any useful form, such as orally, transdermally, tran

snasally, rectally, sublinguinally, subdermally, intraocularly

20

and via inhalation smokeless delivery. In general, an effective
amount of the nicotine antagonist ranges from about). 1 to

about 50 mg per kg of body Weight, preferably about 0.2 to
about 35 mg per kg of body Weight. The compound or com
bination of compounds can be administered as needed, such

25

as once daily or betWeen one and three times daily, for

generally are more potent inhibitors than analogs With shorter

The effects of the compounds of the invention on inhibition

chain lengths (C 1 -C7). Higher a?inity of longer n-alkyl chain

of nicotine-evoked dopamine release is striking, in that
30

pounds bearing n-alkyl groups from C 1 to C4 are loW potency

antagonists (IC5O>l0 uM); the most potent compound is the
C 12 analog, NDDNI (IC5O:9 nM) (Table 1), indicating that a
relatively long n-alkyl chain provides potent inhibition.

35

solubility. In the regression analysis of linearity betWeen
n-alkyl chain length and inhibitory activity, an orderly pro
gression in potency from C1 (NMNI) to C12 (NDDNI) is
observed, With the exception of the n-decyl analog, NDNI,

analogs for [3 H] -nicotine binding sites may re?ect a stronger
association With the nAChR due to an increased lipophilic
interaction of the carbon chain With a region of the protein

near the [3H]-nicotine binding pocket, likely rich in hydro
phobic amino acid residues. Thus, the lipophilic interaction
may stabiliZe the analog-receptor complex, increasing the
inhibitory potency of longer chain analogs.
Scatchard analyses of [3H]-nicotine saturation binding in
the absence and presence of NONI and NDNI indicate that

Therefore, analogs With alkyl chain lengths of 6 to 12 carbon
atoms are preferred, and analogs With alkyl chain lengths of 9
to 12 carbon atoms are more preferred. Analogs With chain
lengths greater than C 12 are less preferred, due to poor Water

length of the n-alkyl chain and a?inity for the [3H]-nicotine
binding site, With the exception of the C8 analog, NONI.

Thus, analogs With longer chain lengths (C9, C10 and C12)

example.
inhibitory potency is linearly related to n-alkyl chain length.
Thus, the greater the number of carbons in the n-alkyl chain,
the greater the potency (i.e., the loWer the IC5O value) for
inhibition of nicotine-evoked [3 H] -dopamine over?oW. Com

?ux through the channel.
The N-n-alkylnicotinium analogs of the invention have
also been evaluated for their af?nity for (x4[32* and 0L7*
nAChRs. These compounds generally exhibit loW a?inity for
0L7* nAChRs. In addition, these N-n-alkylnicotinium analogs
exhibit a?inity for [3 H] -nicotine binding sites across a ~200
fold concentration range, from ~90 nM (NDNI) to ~20 uM
(NONI). A simple linear relationship is observed betWeen the

a?inity for [3H]-nicotine binding sites decreases in the pres
ence of increasing concentrations of either NDNI or NONI,
40

With no change in Bmax value, indicating that these com

pounds interact With the high a?inity [3H]-nicotine binding
site in a competitive manner, suggesting interaction With spe
ci?c amino acid residues involved in [3 H] -nicotine binding or
45

With nearby residues alloWing for steric hindrance of [3H]
nicotine binding.
The high a?inity of NONI to inhibit nicotine-evoked [3H] -

Which unexpectedly does not exhibit inhibitory activity at the

nAChR subtype mediating nicotine-evoked dopamine release

dopamine release from superfused striatal slices and its loW

(Table l). NDNI is believed to exist in solution in a unique
conformation that is different from the conformations of the

binding sites, indicate that NONI has selectivity for nAChR

other N-n-alkylnicotinium analogs.

a?inity for the [3H]-nicotine and [3H]-methyllycaconitine
50

The most potent antagonists in this series of analogs pro

a?inity for the [3H]-methyllycaconitine binding sites and its
lack of inhibition of nicotine-evoked [3 H] -dopamine release

duce 80-1 00% maximal inhibition of the response to nicotine.

Thus, these N-n-alkylnicotinium analogs represent a neW
class of nAChR antagonist, and the most potent compound,
NDDNI, is at least tWo orders of magnitude more potent than

from superfused rat striatal slices, indicates that NDNI has

selectivity for (x4[32* nAChRs. Thus, N-n-alkylnicotinium
55

the classical antagonist, dihydro-[3-erthyroidine (DHBE) as

analogs are useful ligands for de?ning structural topogra
phies of recognition sites of nAChR subtypes through com

puter-assisted modeling.

an inhibitor of nAChRs mediating nicotine-evoked dopamine
release. In addition, kinetic studies (Schild analysis) indicate
that the C8 compound, NONI interacts in a competitive man
ner With these receptors.

subtypes mediating nicotine-evoked dopamine release in
striatum. The high a?inity ofNDNI combined With its lack of

The invention Will noW be described in greater detail by

reference to the folloWing non-limiting examples.
60

Example 1

Unlike agonist molecules, antagonists Which are generally
larger molecules, have been proposed to dock onto the ago

nist-binding site, but extend beyond the region of agonist
binding. The additional structural bulk associated With
antagonist molecules has been proposed to prevent the recep
tor protein from achieving the open channel form. In this
respect, the active N-n-alkylnicotinium analogs are of signi?

N,N'-Pentane- l , 5-diyl-bis-pyridinium Diiodide

(bPPeI)
65

1,5-Diiodopentane (mmol) Was added to a solution (30
mL) of dry pyridine, and the solution heated for 24 hours at

US 8,546,415 B2
10
65° C. The resulting precipitate Was ?ltered, and the product
Washed ?ve times With dry diethyl ether. The resulting yellow

Example 6

solid Was isolated in a 90% yield. 1H NMR (300 MHZ,

N,N'-Undecane-1 ,1'-diyl-bis-pyridinium Dibromide

DMSO-D6) 6 9.14 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H),
8.19 (2H, t, C3&C5-H), 4.62 (2H, t, C'1-CH2), 1.92 (2H, m,
C'2-CH2), 1.25 (1H, m, C'3-CH2).

(bPUB)
1,11-Dibromoundecane (mmol) Was added to a solution

(30 mL) of dry pyridine, and the solution heated for 24 hours
at 650 C. The resulting precipitate Was ?ltered, and the prod
uct Washed ?ve times With dry diethyl ether. The resulting tan
liquid Was isolated in a 91% yield. 1H NMR (300 MHZ,

Example 2

N,N'-Hexane-1,6-diyl-bis-pyridinium Diiodide

(bPHxl)

DMSO-D6) 6 9.18 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H),
8.19 (2H, t, C3&C5-H), 4.63 (2H, t, C'1-CH2), 1.88 (2H, m,
C'2-CH2), 1.22 (7H, m, C'3-6-CH2).

1,6-Diiodohexane (mmol) Was added to a solution (30 mL)
of dry pyridine, and the solution heated for 24 hours at 650 C.

Example 7

The resulting precipitate Was ?ltered, and the product Washed
?ve times With dry diethyl ether. The resulting yelloW solid
Was isolated. 1H NMR (300 MHZ, DMSO-D6) 6 9.11 (2H, d,

N,N'-Dodecane-1 ,12-diyl-bis-pyridinium Dibromide

C2&C6-H), 8.63 (1H, t, C4-H), 8.18 (2H, t, C3&C5-H), 4.59
(2H, t, C'1-CH2), 1.89 (2H, m, C'2-CH2), 1.28 (2H, m, C'3

CH2).

(bPDDB)
1,12-Dibromododecane (mmol) Was added to a solution
20

Example 3

White solid Was isolated in a 93% yield. 1H NMR (300 MHZ,

N,N'-Octane-1,8-diyl-bis-pyridinium Diiodide

(bPOl)

25

1,8-Diiodooctane (mmol) Was added to a solution (30 mL)
of dry pyridine, and the solution heated for 24 hours at 650 C.

The resulting precipitate Was ?ltered, and the product Washed
?ve times With dry diethyl ether. The resulting yelloW solid
Was isolated in a 93% yield. 1H NMR (300 MHZ, DMSO-D6)

6 9.11 (2H, d, C2&C6-H), 8.63 (1H, t, C4-H), 8.18 (2H, t,
C3&C5-H), 4.59 (2H, t, C'1-CH2), 1.89 (2H, m, C'2-CH2),
1.28 (4H, m, C'3&4-CH2); 13C NMR (75 MHZ, DMSO-D6) 6
145.3, 144.5, 127.9, 60.5, 30.6, 28.1, 25.2.

30

Example 8

N,N'-Hexane-1,6-diyl-bis-quinolinium Diiodide

(bQHxl)
35

1,6-Diiodohexane (mmol) Was added to a solution (30 mL)
of dry quinoline, and the solution heated for 24 hours at 650 C.

The resulting precipitate Was ?ltered, and the product Washed
?ve times With dry diethyl ether. The resulting yelloW solid
Was isolated. 1H NMR (300 MHZ, DMSO-D6) 6 9.53 (1H, d,

N,N'-Nonane-1 ,9-diyl-bis-pyridinium Dibromide
40

C2-H), 9.29 (1H, d, C3-H), 8.61 (1H, d, C8-H), 8.50 (1H, d,
C4-H), 8.29 (1H, t, C7-H), 8.18 (1H, t, C5-H), 8.07 (1H, d,
C6-H), 5.09 (2H, t, C'1-CH2), 1.96 (2H, m, C'2-CH2), 1.25
(2H, m, C'3-CH2).

1,9-Dibromononane (mmol) Was added to a solution (30

mL) of dry pyridine, and the solution heated for 24 hours at
650 C. The resulting precipitate Was ?ltered, and the product
Washed ?ve times With dry diethyl ether. The resulting clear
liquid Was isolated in a 87% yield. 1H NMR (300 MHZ,

DMSO-D6) 6 9.17 (2H, d, C2&C6-H), 8.61 (1H, t, C4-H),
8.18 (2H, t, C3&C5-H), 4.63 (2H, t, C'1-CH2), 1.89 (2H, m,
C'2-CH2), 1.22 (5H, m, C'3-5-CH2); 13C NMR (75 MHZ,
DMSO-D6) 6 145.3, 144.5, 127.9, 60.5, 30.7, 28.4, 28.2,

DMSO-D6) 6 9.15 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H),
8.19 (2H, t, C3&C5-H), 4.61 (2H, t, C'1-CH2), 1.88 (2H, m,
C'2-CH2), 1.22 (8H, m, C'3-6-CH2); 13C NMR (75 MHZ,
DMSO-D6) 6 145.3, 144.6, 127.9, 60.7, 30.8, 28.9, 28.8,
28.5, 25.4.

Example 4

(bPNB)

(30 mL) of dry pyridine, and the solution heated for 24 hours
at 650 C. The resulting precipitate Was ?ltered, and the prod
uct Washed ?ve times With dry diethyl ether. The resulting

Example 9

N,N'-Octane-1,8-diyl-bis-quinolinium Diiodide

(bQOI)
50

1,8-Diiodooctane (mmol) Was added to a solution (30 mL)
of dry quinoline, and the solution heated for 24 hours at 650 C.

The resulting precipitate Was ?ltered, and the product Washed
?ve times With dry diethyl ether. The resulting yelloW solid

25.3.

Example 5

N,N'-Decane-1,10-diyl-bis-pyridinium Diiodide

Was isolated in an 89% yield. 1H NMR (300 MHZ, DMSO
55

(bPDl)

D6) 6 9.53 (1H, d, C2-H), 9.29 (1H, d, C3-H), 8.61 (1H, d,
C8-H), 8.50 (1H, d, C4-H), 8.29 (1H, t, C7-H), 8.18 (1H, t,
C5-H), 8.07 (1H, d, C6-H), 5.09 (2H, t, C'1-CH2), 1.96 (2H,
m, C'2-CH2), 1.25 (4H, m, C'3&4-CH2); 13C NMR (75 MHZ,

1,10-Diiododecane (mmol) Was added to a solution (30

mL) of dry pyridine, and the solution heated for 24 hours at
650 C. The resulting precipitate Was ?ltered, and the product

DMSO-D6)6149.5,147.4,137.4,135.6,130.7,129.9,129.7,
122.1, 118.9, 57.3, 29.5, 28.5, 25.7.
60

Washed ?ve times With dry diethyl ether. The resulting yelloW

Example 10

solid Was isolated in a 90% yield. 1H NMR (300 MHZ,

DMSO-D6) 6 9.10 (2H, d, C2&C6-H), 8.63 (1H, t, C4-H),
8.19 (2H, t, C3&C5-H), 4.60 (2H, t, C'1-CH2), 1.89 (2H, m,
C'2-CH2), 1.24 (6H, m, C'3-5-CH2); 13C NMR (75 MHZ,
DMSO-D6) 6 145.3, 144.5, 127.9, 60.6, 30.6, 28.8, 28.1,
25.2.

N,N'-Nonane-1,9-diyl-bis-quinolinium Dibromide

(bQNB)
65

1,9-Dibromononane (mmol) Was added to a solution (30

mL) of dry quinoline, and the solution heated for 24 hours at

US 8,546,415 B2
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65° C. The resulting precipitate Was ?ltered, and the product
Washed ?ve times With dry diethyl ether. The resulting purple

?ve times With dry diethyl ether. The precipitate Was then
dissolved in Water (30 mL) and extracted With chloroform
(3><30 mL). The aqueous layer Was collected and evaporated
to dryness on a rotary evaporator. The resulting pale yelloW
solid Was isolated. 1H NMR (300 MHZ, DMSO-D6) 6 9.03

solid Was isolated in a 92% yield. 1H NMR (300 MHZ,

DMSO-D6) 6 9.68 (1H, d, C2-H), 9.34 (1H, d, C3-H), 8.67
(1H, d, C8-H), 8.55 (1H, d, C4-H), 8.27 (2H, m, C5&C7-H),
8.07 (1H, d, C6-H), 5.09 (2H, t, C'1-CH2), 1.95 (2H, m,
C'2-CH2), 1.19-1.45 (5H, m, C'3-5-CH2).

(1H, s, C2-H), 8.93 (1H, d, C6-H), 8.46 (1H, d, C4-H), 8.08
(1H, t, C5-H), 4.55 (2H, t, C'1-CH2), 2.74 (3H, s, C3-CH3),
2.13 (2H, m, C'2-CH2), 1.46 (2H, m, C'3-CH2).

Example 11
Example 15

N,N'-Decane-1,10-diyl-bis-quinolinium Diiodide

(bQDI)

N,N'-Octane-1,8-diyl-bis-picolinium Diiodide

(bPiOl)

1,10-Diiododecane (mmol) Was added to a solution (30

mL) of dry quinoline, and the solution heated for 24 hours at
650 C. The resulting precipitate Was ?ltered, and the product

1,8-Diiodooctane (mmol) Was added to a solution (30 mL)
of 3-picoline, and the solution heated for 24 hours at 650 C.

Washed ?ve times With dry diethyl ether. The resulting yelloW
solid Was isolated in a 91% yield. 1H NMR (300 MHZ,

DMSO-D6) 6 9.53 (1H, d, C2-H), 9.29 (1H, d, C3-H), 8.61
(1H, d, C8-H), 8.50 (1H, d, C4-H), 8.29 (1H, t, C7-H), 8.18
(1H, t, C5-H), 8.06 (1H, d, C6-H), 5.04 (2H, t, C'1-CH2), 1.96
(2H, m, C'2-CH2), 1.32 (6H, m, C'3-5-CH2); 13C NMR (75

20

MHZ,DMSO-D6)6149.5,147.4,137.4,135.6,130.7,129.9,

The resulting precipitate Was ?ltered, and the product Washed
?ve times With dry diethyl ether. The precipitate Was then
dissolved in Water (30 mL) and extracted With chloroform
(3><30 mL). The aqueous layer Was collected and evaporated
to dryness on a rotary evaporator. The resulting pale yelloW
solid Was isolated in a 94% yield. 1H NMR (300 MHZ,

Example 12

DMSO-D6) 6 9.18 (1H, s, C2-H), 8.96 (1H, d, C6-H), 8.46
(1H, d, C4-H), 8.07 (1H, t, C5-H), 4.62 (2H, t, C'1-CH2), 2.50
(3H, s, C3-CH3), 1.94 (2H, m, C'2-CH2), 1.27 (4H, m, C'3&4

N,N'-Undecane-1,1'-diyl-bis-quinolinium Dibromide

CH2);13C NMR (75 MHZ, DMSO-D6) 6 145.5, 143.9, 141.7,
138.5, 127.1, 60.4, 30.5, 28.1, 25.2, 17.9.

129.7, 122.1, 118.9, 57.3, 29.5, 28.9, 28.5, 25.7.

25

(bQUB)
30

Example 16

1,11-Dibromoundecane (mmol) Was added to a solution

(30 mL) of dry quinoline, and the solution heated for 24 hours
at 650 C. The resulting precipitate Was ?ltered, and the prod
uct Washed ?ve times With dry diethyl ether. The resulting
purple solid Was isolated in a 87% yield. 1H NMR (300 MHZ,

N,N'-Nonane-1,9-diyl-bis-picolinium Dibromide
35

CDCl3) 6 9.54 (1H, d, C2-H), 9.28 (1H, d, C3-H), 8.60 (1H,
d, C8-H), 8.48 (1H, d, C4-H), 8.27 (1H, t, C7-H), 8.16 (1H, t,
C5-H), 8.05 (1H, d, C6-H), 5.03 (2H, t, C'1-CH2), 1.95 (2H,

1,9-Dibromononane (mmol) Was added to a solution (30
mL) of 3-picoline, and the solution heated for 24 hours at 650

m, C'2-CH2), 1.15-1.48 (7H, m, C'3-6-CH2); 13C NMR (75

MHZ, DMSO-d6) 6 149.5, 147.4, 137.4, 135.6, 130.7, 129.9,
129.7, 122.1, 118.9, 57.3, 29.5, 28.9, 28.8, 28.5, 25.7.

40

liquid Was isolated in a 90% yield. 1H NMR (300 MHZ,
45

Dibromide (bQDDB)
1,12-Dibromododecane (mmol) Was added to a solution

(30 mL) of dry quinoline, and the solution heated for 24 hours
at 650 C. The resulting precipitate Was ?ltered, and the prod
uct Washed ?ve times With dry diethyl ether. The resulting

C. The resulting precipitate Was ?ltered, and the product
Washed ?ve times With dry diethyl ether. The precipitate Was
then dissolved in Water (30 mL) and extracted With chloro
form (3 x30 mL). The aqueous layer Was collected and evapo
rated to dryness on a rotary evaporator. The resulting tan

Example 13

N,N'-Dodecane-1,12-diyl-bis-quinolinium

(bPiNB)

DMSO-D6) 6 9.17 (1H, s, C2-H), 9.04 (1H, d, C6-H), 8.47
(1H, d, C4-H), 8.08 (1H, t, C5-H), 4.60 (2H, t, C'1-CH2), 2.50
(3H, s, C3-CH3), 1.92 (2H, m, C'2-CH2), 1.27 (5H, m, C'3
5-CH2); 13C NMR (75 MHZ, DMSO-D6) 6 145.5, 144.1,
141.8, 138.5, 127.1, 60.4, 30.7, 28.5, 28.3, 25.4, 17.9.

50

Example 17

yelloW solid Was isolated in a 92% yield. 1H NMR (300 MHZ,

DMSO-D6) 6 9.58 (1H, d, C2-H), 9.29 (1H, d, C3-H), 8.61
(1H, d, C8-H), 8.50 (1H, d, C4-H), 8.29 (1H, t, C7-H), 8.18
(1H, t, C5-H), 8.04 (1H, d, C6-H), 5.04 (2H, t, C'1-CH2), 1.95
(2H, m, C'2-CH2), 1.2-1 .4 (8H, m, C'3-6-CH2); l3CNMR (75

N,N'-Decane-1,10-diyl-bis-picolinium Diiodide
55

1,10-Diiododecane (mmol) Was added to a solution (30
mL) of 3-picoline, and the solution heated for 24 hours at 650

MHZ,DMSO-D6)6149.5,147.4,137.4,135.6,130.7,129.9,
129.7, 122.1, 118.9, 57.3, 29.5, 28.9, 28.8, 28.5, 25.7.
Example 14

60

N,N'-Hexane-1,6-diyl-bis-picolinium Diiodide

(bPiOl)
1,6-Diiodohexane (mmol) Was added to a solution (30 mL)
of 3-picoline, and the solution heated for 24 hours at 650 C.

The resulting precipitate Was ?ltered, and the product Washed

(bPiDl)

65

C. The resulting precipitate Was ?ltered, and the product
Washed ?ve times With dry diethyl ether. The precipitate Was
then dissolved in Water (30 mL) and extracted With chloro
form (3 x30 mL). The aqueous layer Was collected and evapo
rated to dryness on a rotary evaporator. The resulting off White
solid Was isolated in a 92% yield. 1H NMR (300 MHZ,

CDCl3) 6 9.04 (1H, s, C2-H), 8.94 (1H, d, C6-H), 8.46 (1H, d,
C4-H), 8.06 (1H, t, C5-H), 4.58 (2H, t, C'1-CH2), 2.50 (3H, s,
C3-CH3), 1.90 (2H, m, C'2-CH2), 1.27 (6H, m, C'3-5-CH2).

US 8,546,415 B2
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Example 18

ture for 5 minutes. 1,8-Diiodooctane (15.4 mmol) Was added
to the solution and the mixture stirred and re?uxed for 3 days.

N,N'-Undecane-1 ,1'-diyl-bis-picolinium Dibromide

The mixture Was then evaporated under reduced pressure to
remove the solvent and the resulting oil Was treated With an

(bPiUB)

aqueous mixture of sodium bicarbonate. The aqueous mix
ture Was extracted With ethyl ether (3 x50 mL) and chloroform
(3x50 mL) and the aqueous layer collected and Was evapo
rated to dryness on a rotary evaporator, and the resulting solid

1,11-Dibromoundecane (mmol) Was added to a solution

(30 mL) of 3-picoline, and the solution heated for 24 hours at
65° C. The resulting precipitate Was ?ltered, and the product
Washed ?ve times With dry diethyl ether. The precipitate Was
then dissolved in Water (30 mL) and extracted With chloro
form (3 x30 mL). The aqueous layer Was collected and evapo

Was treated With chloroform and ?ltered. The ?ltrate Was

collected and evaporated to dryness. The resulting yelloW oil
Was isolated in a 15% yield. 1H NMR (300 MHZ, CDCl3), 6

rated to dryness on a rotary evaporator. The resulting tan

9.58 (1H, s, C2-H), 9.50 (1H, d, C6-H), 8.47 (1H, d, C4-H),

liquid Was isolated in a 90% yield. 1H NMR (300 MHZ,

8.03 (1H, m. C3-H), 4.96 (2H, t, C"1-CH2), 3.65 (1H, t,

DMSO-D6) 6 9.10 (1H, s, C2-H), 8.98 (1H, d, C6-H), 8.46
(1H, d, C4-H), 8.07 (1H, t, C5-H), 4.58 (2H, t, C'1-CH2), 2.50
(3H, s, C3-CH3), 1.90 (2H, m, C'2-CH2), 1.26 (7H, m, C'3
6-CH2); 13C NMR (75 MHZ, DMSO-D6) 6 145.5, 144.0,
141.8, 138.5, 127.1, 60.5, 30.7, 28.8, 28.7, 28.4, 25.4, 17.9.
Example 19

pyrrolidine CH2), 3.24 (1H, t, pyrrolidine CH2), 2.49 (2H, m,
C"2-CH2), 2.25 (3H, s, pyrrolidine N%H3), 1.60-2.19 (5H,
m, pyrrolidine CH2CH2), 1.40-1.60 (4H, m, C"3&4-CH2);
13C NMR (75 MHZ, CDCl3) 6 146.9, 143.8, 143.6, 143.5,
128.3, 66.8, 61.7, 57.0, 40.8, 36.1, 32.0, 27.7, 25.2, 23.5.
20

Example 22

N,N'-Dodecane-1,12-diyl-bis-picolinium Dibromide

N,N'-Nonane- 1 ,9-diyl-bis-nicotinium Dibromide

(bPiDDB)
1,12-Dibromododecane (mmol) Was added to a solution

(30 mL) of 3-picoline, and the solution heated for 24 hours at
650 C. The resulting precipitate Was ?ltered, and the product
Washed ?ve times With dry diethyl ether. The precipitate Was
then dissolved in Water (30 mL) and extracted With chloro
form (3 x30 mL). The aqueous layer Was collected and evapo

(bNNB)
25

S-(—)-Nicotine (30.8 mmol) Was dissolved in glacial acetic

30

acid (35 mL) and the solution Was stirred at ambient tempera
ture for 5 minutes. 1,9-Dibromononane (15.4 mmol) Was
added to the solution and the mixture stirred and re?uxed for
3 days. The mixture Was then evaporated under reduced pres

rated to dryness on a rotary evaporator. The resulting tan

sure to remove the solvent and the resulting oil Was treated

liquid Was isolated in a 92% yield. 1H NMR (300 MHZ,

With an aqueous mixture of sodium bicarbonate. The aqueous

CDCl3) 6 9.04 (1H, s, C2-H), 8.94 (1H, d, C6-H), 8.46 (1H, d,
C4-H), 8.16 (1H, t, C5-H), 4.55 (2H, t, C'1-CH2), 2.50 (3H, s,
C3-CH3), 1.90 (2H, m, C'2-CH2), 1.25 (8H, m, C'3-6-CH2).

mixture Was extracted With ethyl ether (3x50 mL) and chlo
roform (3x50 mL) and the aqueous layer collected and Was
evaporated to dryness on a rotary evaporator, and the resulting

35

solid Was treated With chloroform and ?ltered. The ?ltrate

Example 20

Was collected and evaporated to dryness. The resulting yelloW
oil Was isolated in a % yield. 1H NMR (300 MHZ, CDCl3), 6

N,N'-Hexane-1,6-diyl-bis-nicotinium Diiodide

(bNHxl)

9.75 (1H, s, C2-H), 9.56 (1H, d, C6-H), 8.49 (1H, d, C4-H),
40

pyrrolidine CH2), 3.25 (1H, t, pyrrolidine CH2), 2.48 (2H, m,
C"2-CH2), 2.25 (3H, s, pyrrolidine N%H3), 1.60-2.23 (5H,
m, pyrrolidine CH2CH2), 1.30-1.60 (5H, m, C"3-5-CH2).

S-(—)-Nicotine (30.8 mmol) Was dissolved in glacial acetic
acid (35 mL) and the solution Was stirred at ambient tempera
ture for 5 minutes. 1,6-Diiodohexane (15.4 mmol) Was added
to the solution and the mixture stirred and re?uxed for 3 days.

45

The mixture Was then evaporated under reduced pressure to
remove the solvent and the resulting oil Was treated With an
aqueous mixture of sodium bicarbonate. The aqueous mix

ture Was extracted With ethyl ether (3 x50 mL) and chloroform
(3><50 mL) and the aqueous layer collected and Was evapo
rated to dryness on a rotary evaporator, and the resulting solid

Example 22

N,N'-Decane-1,10-diyl-bis-nicotinium Diiodide

(bNDl)
50

S-(—)-Nicotine (30.8 mmol) Was dissolved in glacial acetic
acid (35 mL) and the solution Was stirred at ambient tempera
ture for 5 minutes. 1,10-Diiododecane (15.4 mmol) Was
added to the solution and the mixture stirred and re?uxed for
3 days. The mixture Was then evaporated under reduced pres

Was treated With chloroform and ?ltered. The ?ltrate Was

collected and evaporated to dryness. The resulting yelloW oil
Was isolated. 1H NMR (300 MHZ, CDCl3), 6 9.44 (1H, s,

C2-H), 9.38 (1H, d, C6-H), 8.44 (1H, d, C4-H), 8.13 (1H, m.
C3-H), 4.95 (2H, t, C"1-CH2), 4.03 (1H, t, pyrrolidine CH2),
3.25 (1H, t, pyrrolidine CH2), 2.49 (2H, m, C"2-CH2), 2.23
(3H, s, pyrrolidine N4CH3), 1.60-2.19 (5H, m, pyrrolidine
CH2CH2), 1.30-1.55 (2H, m, C"3-CH2).

8.08 (1H, m. C3-H), 5.05 (2H, t, C"1-CH2), 3.65 (1H, t,

55

sure to remove the solvent and the resulting oil Was treated
With an aqueous mixture of sodium bicarbonate. The aqueous

mixture Was extracted With ethyl ether (3x50 mL) and chlo
roform (3x50 mL) and the aqueous layer collected and Was
evaporated to dryness on a rotary evaporator, and the resulting
60

solid Was treated With chloroform and ?ltered. The ?ltrate

Example 21

Was collected and evaporated to dryness. The resulting yelloW
oil Was isolated in a 27% yield. 1H NMR (300 MHZ, CDCl3)

N,N'-Octane-1,8-diyl-bis-nicotinium Diiodide

6 9.55 (1H, s, C2-H), 9.44 (1H, d, C6-H), 8.53 (1H, d, C4-H),
8.09 (1H, m. C3-H), 4.98 (2H, t, C"1-CH2), 3.74 (1H, t,
pyrrolidine CH2), 3.30 (1H, t, pyrrolidine CH2, 2.50 (2H, m,
C"2-CH2), 2.29 (3H, s, pyrrolidine N%H3), 1.65-2.20 (5H,
m, pyrrolidine CH2CH2), 1.30-1.57 (6H, m, C"3-5-CH2); l3C

(bNOl)
65

S-(—)-Nicotine (30.8 mmol) Was dissolved in glacial acetic
acid (35 mL) and the solution Was stirred at ambient tempera

US 8,546,415 B2
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NMR (75 MHZ, CDC13) 6 146.6, 143.9><2, 143.4, 128.4, 66.9,
61.9, 57.0, 40.8, 36.1, 32.1, 28.5, 28.2, 25.8, 23.5.

Example 26

N,N'-Octane-1,8-diyl-bis-isoquinolinium Diiodide

Example 23

(blQOl)

N,N'-Undecane-1 ,1'-diyl-bis-nicotinium Dibromide

1,8-Diiodooctane (mmol) Was added to a solution (30 mL)
of isoquinoline, and the solution heated for 24 hours at 650 C.

(bNUB)

The resulting precipitate Was ?ltered, and the product Washed
?ve times With dry diethyl ether. The resulting yelloW solid

S-(—)-Nicotine (30.8 mmol) Was dissolved in glacial acetic

Was isolated in an 92% yield. 1H NMR (300 MHZ, DMSO

acid (35 mL) and the solution Was stirred at ambient tempera
ture for 5 minutes. 1,11-Dibromoundecane (15.4 mmol) Was
added to the solution and the mixture stirred and re?uxed for
3 days. The mixture Was then evaporated under reduced pres

D6) 6 10.05 (1H, d, C1-H), 8.77 (1H, d, C3-H), 8.58 (1H, d,
C8-H), 8.48 (1H, d, C4-H), 8.35 (1H, d, C7-H), 8.26 (1H, t,
C5-H), 8.07 (1H, t, C6-H), 4.68 (2H, t, C'1-CH2), 2.00 (2H,
m, C'2-CH2), 1.30 (4H, m, C'3&4-CH2).

sure to remove the solvent and the resulting oil Was treated
With an aqueous mixture of sodium bicarbonate. The aqueous

Example 27

mixture Was extracted With ethyl ether (3x50 mL) and chlo
roform (3x50 mL) and the aqueous layer collected and Was
evaporated to dryness on a rotary evaporator, and the resulting
solid Was treated With chloroform and ?ltered. The ?ltrate

N,N'-Nonane-1,9-diyl-bis-isoquinolinium Dibromide

(blQNB)

Was collected and evaporated to dryness. The resulting yelloW
oil Was isolated in a % yield. 1H NMR (300 MHZ, CDCl3) 6

1,9-Dibromononane (mmol) Was added to a solution (30
mL) of isoquinoline, and the solution heated for 24 hours at
650 C. The resulting precipitate Was ?ltered, and the product

9.70 (1H, s, C2-H), 9.47 (1H, d, C6-H), 8.49 (1H, d, C4-H),

Washed ?ve times With dry diethyl ether. The resulting purple

20

solid Was isolated in a 92% yield. 1H NMR (300 MHZ,

8.12 (1H, m. C3-H), 5.02 (2H, t, C"1-CH2), 3.65 (1H, t,

pyrrolidine CH2), 3.26 (1H, t, pyrrolidine CH2), 2.49 (2H, m,
C"2-CH2), 2.25 (3H, s, pyrrolidine N%H3), 1.60-2.20 (5H,
m, pyrrolidine CH2CH2), 1.20-1 .50 (8H, m, C"3-6-CH2); 13C
NMR (75 MHZ, CDCl3) 6 146.5, 144.2, 143.7, 143.5, 128.4,
66.9, 61.9, 56.9, 40.7, 36.1, 32.2, 28.8, 28.7, 28.6, 25.9, 23.4.

25

DMSO-D6) 6 10.17 (1H, d, C1-H), 8.85 (1H, d, C3-H), 8.62
(1H, d, C8-H), 8.49 (1H, d, C4-H), 8.36 (2H, d, C7-H), 8.26
(2H, t, C5-H), 8.08 (1H, t, C6-H), 4.72 (2H, t, C'1-CH2), 2.02
(2H, m, C'2-CH2), 1.78 (1H, m, C'3-CH2), 1.19-1.50 (4H, m,

C'3-5-CH2).
30

Example 28

Example 24

N,N'-Decane-1,10-diyl-bis-isoquinolinium Diiodide
N,N'-Dodecane-1,12-diyl-bis-nicotinium Dibromide

(blQDl)

(bNDDB)
35

acid (35 mL) and the solution Was stirred at ambient tempera

1,10-Diiododecane (mmol) Was added to a solution (30
mL) of isoquinoline, and the solution heated for 24 hours at
650 C. The resulting precipitate Was ?ltered, and the product

ture for ?ve minutes. 1,12-Dibromododecane (15.4 mmol)

Washed ?ve times With dry diethyl ether. The resulting yelloW

S-(—)-Nicotine (30.8 mmol) Was dissolved in glacial acetic
Was added to the solution and the mixture stirred and re?uxed

for 3 days. The mixture Was then evaporated under reduced

solid Was isolated in a 92% yield. 1H NMR (300 MHZ,
40

DMSO-D6) 6 10.07 (1H, d, C1-H), 8.78 (1H, d, C3-H), 8.58
(1H, d, C8-H), 8.48 (1H, d, C4-H), 8.36 (1H, d, C7-H), 8.26
(1H, t, C5-H), 8.07 (1H, t, C6-H), 4.69 (2H, t, C'1-CH2), 2.0
(2H, m, C'2-CH2), 1.15-1.50 (6H, m, C'3-5-CH2).

45

Example 29

pressure to remove the solvent and the resulting oil Was
treated With an aqueous mixture of sodium bicarbonate. The

aqueous mixture Was extracted With ethyl ether (3x50 mL)
and chloroform (3x50 mL) and the aqueous layer collected
and Was evaporated to dryness on a rotary evaporator, and the
resulting solid Was treated With chloroform and ?ltered. The

N,N'-Undecane-1,1'-diyl-bis-isoquinolinium Dibro
mide (blQUB)

?ltrate Was collected and evaporated to dryness. The resulting
yelloW liquid Was isolated in a 35% yield. 1H NMR (300

MHZ, CDCl3) 6 9.66 (1H, s, C2-H), 9.38 (1H, d, C6-H), 8.46
(1H, d, C4-H), 8.10 (1H, m. C3-H), 5.01 (2H, t, C"1-CH2),
3.61 (1H, t, pyrrolidine CH2), 3.25 (1H, t, pyrrolidine CH2),
2.45 (2H, m, C"2-CH2), 2.23 (3H, s, pyrrolidine NiCH3),
1.60-2.19 (5H, m, pyrrolidine CH2CH2), 1.20-1.50 (8H, m,
C"3-6-CH2); 13C NMR (75 MHZ, CDCl3) 6 146.6, 144.2,
143.7, 143.4, 128.5, 67.0, 62.0, 60.0, 40.8, 36.1, 32.4, 29.0,
28.8, 28.7, 26.0, 23.5.

50
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Example 25

N,N'-Hexame-1,6-diyl-bis-isoquinolinium Diiodide

1,11-Dibromoundecane (mmol) Was added to a solution

(30 mL) of isoquinoline, and the solution heated for 24 hours
at 650 C. The resulting precipitate Was ?ltered, and the prod
uct Washed ?ve times With dry diethyl ether. The resulting
off-White solid Was isolated. 1H NMR (300 MHZ, DMSO-D6)

6 10.07 (1H, d, C1-H), 8.78 (1H, d, C3-H), 8.57 (1H, d,
C8-H), 8.48 (1H, d, C4-H), 8.35 (1H, d, C7-H), 8.25 (1H, t,
C5-H), 8.07 (1H, t, C6-H), 4.69 (2H, t, C'1-CH2), 2.0 (2H, m,
C'2-CH2), 1.73 (1H, m, C'3-CH2), 1.15-1.50 (6H, m, C'3-6

CH2).
60

(blQHxl)

Example 30

1,6-Diiodohexane (mmol) Was added to a solution (30 mL)
of isoquinoline, and the solution heated for 24 hours at 650 C.

N,N'-Dodecane-1,12-diyl-bis-isoquinolinium

The resulting precipitate Was ?ltered, and the product Washed
?ve times With dry diethyl ether. The resulting yelloW solid
Was isolated.

Dibromide (blQDDB)
65

1,12-Dibromododecane (mmol) Was added to a solution

(30 mL) of isoquinoline, and the solution heated for 24 hours

US 8,546,415 B2
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at 65° C. The resulting precipitate Was ?ltered, and the prod
uct Washed ?ve times With dry diethyl ether. The resulting

TABLE 1

off-White solidWas isolated. 1H NMR (300 MHZ, DMSO-D6)

Speci?c Binding of [3H]—Nicotine to Rat Striatal Nicotinic
Acetvlcholine Receptors in the Presence of bis-Alkvl Pvridino Analogs

6 10.06 (1H, d, C1-H), 8.78 (1H, d, C3-H), 8.58 (1H, d,
C8-H), 8.48 (1H, d, C4-H), 8.35 (1H, d, C7-H), 8.25 (1H, t,
C5-H), 8.07 (1H, t, C6-H), 4.70 (2H, t, C'1-CH2), 2.0 (2H, m,

Compound

C'2-CH2), 1.75 (1H, m, C'3-CH2), 1.15-1.40 (7H, m, C'3-6

NONI
NDNI

CH2).

DHBE

Kl- (pM)"
49.3
0.1 1

0.15

bPPeI

>100

bPHxI

Example 31

[3H]Nicotine Binding Assay
Striata from tWo rats Were dissected, pooled, and homog
eniZed With a Tamar polytron in 10 volumes of ice-cold modi

?ed Krebs-HEPES buffer (20 mM HEPES, 118 mM NaCl,
4.8 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, adjusted to pH
7.5). The homogenates Were incubated at 37° C. for ?ve
minutes and centrifuged at 15,000 g for 20 minutes. The pellet
Was resuspended in ten volumes of ice-cold MilliQ Water,
incubated for ?ve minutes at 37° C., and centrifuged at 15,000
g for 20 minutes The second pellet Was then resuspended in
ten volumes of fresh ice-cold 10% Krebs-HEPES buffer,
incubated at 37° C., and centrifuged at 15,000 g for 20 min
utes. The latter sequence of resuspension, incubation, and
centrifugation Was repeated. The pellet Was froZen under
fresh 10% Krebs-HEPES buffer and stored at —40° C. until
assay. Upon assay, the pellet Was resuspended in the Krebs
HEPES buffer, incubated at 37° C. for ?ve minutes, and
centrifuged at 15,000 g for 20 minutes. The ?nal pellet Was
resuspended in 3 .6 ml ice-cold MilliQ Water Which provided

20

25
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NDZ’

bPOI
bPNB
bPDI
bPUB
bPDDB
bPiHxI
bPiOI
bPiNB
bPiDI
bPiUB
bPiDDB

33 .9
24.1
18.6
14.4
9.14
ND
>100
66.7
>100
82.0
33 .0

bQHxI
bQOI
bQNB
bQDI

ND
>100
20.1
>100

bQUB

38.3 (n = 2)

bQDDB
bIQHxI
bIQOI
bIQNB
bIQDI
bIQUB
bIQDDB

>100
ND
>100
>100
>100
ND
>100

bNHxI
bNOI
bNNB
bNDI
bNUB
bNDDB

ND
1.50
4.31
0.28
0.37
1 .43

“Data are expressed as frnol/rng ofprotein ofat least 3 independent experiments. Speci?c
35 binding is calculated as the difference between the total binding of3 nM [3H]-nicotine and
nonspeci?c binding in the presence oflO pM cold nicotine.
= Not Determined

for approximately 200 pg protein per 100 pl aliquot. Compe
tition assays Were performed in duplicate in a ?nal volume of

200 pl Krebs-HEPES buffer containing 250 mmol Tris buffer
(pH 7.5 at 4° C.). Reactions Were initiated by addition of 100

Example 32
40

[3H]MLA Binding Assay

pl of membrane suspension to 3 mM [3H]nicotine (50 pl) and
one of at least nine concentrations of analog (50 pl). After a 90
minute incubation at 4° C., reactions Were terminated by
dilution of the samples With 3 ml of ice-cold Krebs-HEPES

45

buffer folloWed immediately by ?ltration through Whatman
GF/B glass ?ber ?lters (presoaked in 0.5% polyethylene
imine) using a Brandel Cell Harvester. Filters Were rinsed
three times With 3 ml of ice-cold Krebs-HEPES buffer, trans
ferred to scintillation vials, and 5 ml scintillation cocktail

50

branes. The results are summariZed in Table 1. Furthermore,

trifugation at the above parameters. The ?nal pellet Was
stored at —20° C. under 4.6 ml of the incubation buffer and
55

The binding of [3H]MLA to probe (x7-type neuronal nico

60

duced by NONI, NDNI, and DHBE. All of the compounds
examined displaced [3H]nicotine binding With loWer af?ni

labelling (x7-type neuronal nicotinic acetylcholine receptors,’
Neuropharmocology, 38, 679-690 (1999). [3H]MLA (25.4
Ci/mmol) Was purchased from Tocris Cookson Ltd., Bristol,

ties than DHBE. HoWever, bNDl had a value approaching the
dinium series demonstrated an increase in a?inity for the
receptor as the chain length of the carbon bridge increased.

Was suspended just before the incubation With radioligand.
tinic acetylcholine receptors Was measured using a modi?ca
tion of the method of Davies et al., “Characterisation of the
binding of [3H]methyllycaconitine: a neW radioligand for

the displacement by the analogs Was compared to that pro

K- of DHBE and NDNI. Additionally, the N-alkyl-bis-pyri

(setting 40) in 20 volumes of ice-cold hypotonic buffer (2 mM
HEPES, 14.4 mM NaCl, 0.15 mM KCl, 0.2 mM CaCl2 and
0.1 mM MgSO4, pH:7.5). The homogenate Was incubated at
37° C. for ten minutes and centrifuged at 25,000><g for 15
minutes at 40° C. The pellet Was Washed three times more by
resuspension in the 20 volumes of the same buffer and cen

(Research Products lntemational Corp., Mt. Prospect, Ill.)
added. Nonspeci?c binding determined in triplicate Was
de?ned as binding in the presence of 10 pM nicotine. Binding
parameters Were determined using the Weighted, least
squares non-linear regression.
The bis-alkyl pyridino analogs Were evaluated for their
ability to displace [3H]nicotine binding from rat striatal mem

Rat brain Was dissected into the Whole brain tissue Without
cortex, striatum and cerebellum and Was froZen in liquid
nitrogen and stored at —70° C. until use.
The brain tissue Was homogenized With a Tekmar Polytron

65

UK. Binding Was performed in duplicate, in a ?nal volume of
250 ml of the incubation medium, containing 20 mM HEPES,
144 mM NaCl, 1.5 mM KCl, 2 mM CaCl2, 1 mM MgSO4 and
0.05% BSA, pH:7.5. Reaction Was initiated by the addition

of 100 pl of membrane suspension to the samples containing

US 8,546,415 B2
19

20

a desired concentration of test compounds and 2.5 mM [3 H]
MLA (?nal concentration) and incubated for 2 hours at room
temperature. Total binding Was measured in the absence of
unlabelled ligand and nonspeci?c binding Was determined in
the presence of 1 uM unlabelled MLA. The binding reaction
Was terminated by dilution of samples With 3 ml of ice-cold
incubation buffer folloWed by immediate ?ltration through

Example 33

[3H] DA Release Assay
5

Rat striatal slices (500 um thickness, 6-8 mg Wet Weight)
Were incubated for 30 minutes in Krebs buffer (118 mM

NaCl, 4.7 mM KCl, 1.2 mM MgCl2, 1.0 mM NaH2PO4, 1.3
mM CaCl2, 11.1 mM glucose, 25 mM NaHCO3, 0.11 mM
L-ascorbic acid, and 0.004 mM disodium EDTA; pH 7.4, and

presoaked in 0.5% polyethylenimine glass ?ber ?lters (S&S,
grade #32) using a Brandel harvester system. Filters Were
rinsed three times With 3 ml of ice-cold buffer, transferred to
scintillation vials and 4 ml of scintillation cocktail Was added.
Protein Was measured using the Bradford dye-binding proce

saturated With 95% 02/ 5% CO2) in a metabolic shaker at 340
C. Slices Were rinsed With 15 mL of fresh buffer and incu
bated for an additional 30 minutes in fresh buffer containing

0.1 uM [3H]DA (6 slices/3 ml). Subsequently, slices Were

dure With bovine serum albumin as the standard.

In order to determine if these compounds have selectivity

rinsed With 15 ml of fresh buffer and transferred to a glass

at the (X7 receptor subtype, the bis-alkyl pyridino analogs
Were evaluated for their ability to displace [3H]MLA binding

superfusion chamber. Slices Were superfused(1.0 ml/min) for
60 minutes With Krebs buffer containing nomifensine (10

from rat brain membranes, as a re?ection of their interaction

11M) and pargyline (10 11M) and maintained at 340 C., pH 7.4,

With the (X7 receptor (Table 2). In addition, the classical (X7
receptor antagonist ot-bungarotoxin Was also examined in this
assay for comparison. ot-Bungarotoxin afforded a K- value of
28.6154 nM in this assay. The results from the competition

With continual aeration (95% O2/ 5% CO2). TWo ?ve minute
20

and remained in the buffer until 12 consecutive ?ve minute

binding assay shoWed that N,N'-dodecane-1,12-diyl-bis-py
ridinium; Dibromide (bPDDB) and the N-alkyl-bis-quino
linium analogs demonstrated moderate binding a?inity in the

samples Were collected. Subsequently, S-(—)-nicotine (10
11M) Was added to the buffer and an additional 12 consecutive

?ve minute samples Were collected. At the end of the experi
ment, each slice Was solubiliZed and the [3H] content of the
tissue determined.

[3 H] MLA assay, While the other compounds shoWed no a?in
ity no af?nity for the (X7 subtype.
TABLE 2

30

Compound

K,- (pM)"
>100
>100

DH[5E
bPPeI
bPHxI
bPOI
bPNB
bPDI
bPUB
bPDDB
bPiHxI
bPiOI
bPiNB
bPiDI
bPiUB
bPiDDB

tion and Was expressed as a percentage of total tritium. Basal
35

NDZ’
>100
ND
>100
>100
>100
50.2
35 .6
ND
>100
>100
>100
>100
>100

bQHxI
bQOI

ND
2.01

bQNB

3 .40

bQDI
bQUB

7.32
2.44

Radioactivity in the superfusate and tissue samples Was
determined by liquid scintillation spectroscopy. Fractional
release for tritium collected in each sample Was divided by the
total tritium present in the tissue at the time of sample collec

[3HlMLA Binding in the Presence ofbis-Alkyl Pyridino Analogs

NONI
NDNI

samples (5 ml each) Were collected to determine basal out

?oW of [3H]DA. bis-Alkyl pyridino analogs Were added to the
superfusion buffer after the collection of the second sample

40

[3H]out?oW Was calculated from the average of the tritium
collected in the tWo ?ve minute samples just before addition
of the bis-alkyl pyridino analog. The sum of the increase in
collected tritium resulting from either exposure to the test
compound or exposure to S-(—)-nicotine in the absence and

presence of the test compound equaled total [3H]over?oW.
[3H]Over?oW Was calculated by subtracting the [3H]out?oW
during an equivalent period of prestimulation from the values
in samples collected during and after drug exposure. Inas
much as the radiolabelled compounds Were not separated and
identi?ed, the tritium collected in superfusate is referred to as

45

either [3H]out?oW or [3H]over?oW, rather than as [3H]DA.

[3 H]Over?oW primarily represents [3 H]DA in the presence of
nomifensine and pargyline in the superfusion buffer.
The bis-alkyl pyridino analogs Were evaluated for their
ability to evoke [3H]DA release from rat striatal slices. In
50

addition, the classical competitive nicotinic antagonist DHBE
Was also examined in this assay for comparison. None of the

bQDDB

1 .57

compounds examined had any signi?cant [3H]DA releasing

bIQHxI
bIQOI

ND
8.55

properties in this assay in the concentration range tested.
Since striatal nicotine-evoked [3H]DA release is thought to be

bIQNB
bIQDI

13 .1
5 .50

bIQUB
bIQDDB

24.1
12.3

hNHxI
bNOI
bNNB
bNDI
bNUB
bNDDB

ND
>100
>100
>100
>100
>100

55

activity at the 0662* subtype.
60

Tata are expressed as frnol/rng of protein of 3 independent experiments. Speci?c binding is
calculated as the difference between the total binding of2.5 nM [3H]-MLA to the receptors
65
alone and its nonspeci?c binding in the presence of 1 11M cold MLA.
bND = Not Determined

mediated through a mechanism involving the (1362* receptor
subtype, these compounds do not possess signi?cant agonist
The bis-alkyl pyridino analogs Were also evaluated for
their ability to inhibit nicotine-evoked [3H]DA release. In
these experiments, the striatal slices Were superfused for 60
minutes With various concentrations of the analogs prior to
nicotine (10 11M) exposure. Antagonist activity Was evaluated

by comparing the nicotine-evoked [3H]over?oW in the
absence and presence of the analogs. The relative order of

potency of the bis-alkyl pyridino analogs for inhibition of
nicotine-evoked [3H] DA release from rat striatal slices is
illustrated in Table 3 by a comparison of their IC5O values.

US 8,546,415 B2
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TABLE 3

with diethyl ether (3x50 mL). The aqueous solution was then
lyophilized to afford 19 as a crystalline solid.
All compounds were characterized by 1H and 13 C NMR

Comparative IC5Os for bis-Alkyl Pyridino Analogs in the S-(—)
nicotine-evoked [3H]DA Release Assay

Compound

IC5O (11M)

NONI
NDNI

0.62
>100

DH[5E
bPPeI

1.0
NDZ’

bPHxI
bPOI
bPNB
bPDI
bPUB
bPDDB
bPHxI
bPiOI
bPiNB
bPiDI
bPiUB
bPiDDB

ND
>1.0"
ND
>1.0"
ND
1.0
ND
ND
ND
ND
ND
0.002

bQHxI
bQOI
bQNB
bQDI
bQUB
bQDDB
bIQHxI
bIQOI
bIQNB
bIQDI
bIQUB
bIQDDB

ND
ND
ND
ND
ND
0.020
ND
ND
ND
ND
ND
ND

bNHxI
bNOI
bNNB
bNDI
bNUB
bNDDB

ND
ND
ND
ND
ND
4.37

“Compunds only tested for two concentration points 0.1 and 1.0 pM
bND = Not Determined

spectroscopy, mass spectroscopy and elemental analysis.

Biological Assays
Subjects.
Male Sprague-Dawley rats (225-250 g) were obtained
from Harlan Industries (Indianapolis, Ind.) and housed two
per cage with free access to food and water in the Division of

Lab Animal Resources in the College of Pharmacy at the
University of Kentucky. All experiments were carried out in
accordance with the 1996 NIH Guide for the Care and Use of

Laboratory Animals and were approved by the Institutional
Animal Care and Use Committee at the University of Ken

tucky.

20

[3H]-Dopamine Over?ow from Superfused Striatal Slices.
[3H]-Dopamine release assays were performed according
to Dwoskin, L. P., and Zahniser, N. R., .1. Pharmacol. Exp.
Then 1986, 239, 442; Miller, D. K., et al., J. Pharmacol. Exp.
Ther 2002, 302, 1113; Reuben, M., Clarke, P. B., Neurophar
macology 2000, 39, 290, with minor modi?cations. Striatal
coronal slices (500 um, 4-6 mg) were obtained and incubated
for 30 minutes in Krebs’ buffer (in mM: 118 NaCl, 4.7 KCl,

1.2 MgCl2, 1 NaH2PO4, 1.3 CaCl2, 11.1 glucose, 25
25

NaHCO3, 0.11 L-ascorbic acid and 0.004 disodium EDTA,
pH 7.4, saturated with 95% O2/5% CO2) in a metabolic
shaker at 34° C. Slices were incubated with 0.1 uM (?nal

concentration) of [3 H]-dopamine during the latter 30 minutes
30

of the 60-minute incubation period. Each slice was trans
ferred to a glass superfusion chamber maintained at 34° C.

and superfused (1 ml/min) with Krebs’ buffer containing

nomifensine (10 uM) and pargyline (10 uM) to inhibit [3H]
dopamine reuptake after release into the extracellular space,

ensuring that [3H]-over?ow primarily represented [3H]
35

dopamine. Sample collection (5 -minute; 5 mL) began after 60
minutes of superfusion. The ability of N-n-alkylated nico

tinium,
Example 34

Compounds 1-3 (FIG. 3) were prepared by reacting S-(—)

N-n-alkylated

pyridinium,

conformationally

restricted N-n-alkylated nicotinium and bis-azaaromatic qua
40

nicotine with the appropriate n-alkyl iodide in glacial acetic

ternary ammonium analogs to evoke [3H]-dopamine release
(intrinsic activity) and to inhibit nicotine-evoked [3H]
dopamine release (act as antagonists) were determined. At the
end of the experiment, each slice was solubilized, and the

acid, utilizing the procedure described by Crooks, et al., Drug

restricted racemic syn- and anti-nicotine analogs 8-12 and

[3H]-content of the tissue determined. Release during each
minute was normalized for total tissue [3 H] -content. Analog
induced intrinsic activity and inhibitory activity were deter
mined using slices from the same rat (repeated-measures

13-17, respectively (FIG. 3), were prepared via regiospeci?c

design).

alkylation of the pyridine-N atom of the corresponding free
base. The syn-free base was synthesized from 7-aza-1-tetral

The amount of [3H] in each sample was calculated by
dividing the total [3H] collected in each sample by the total in

Dev. Res. 1995, 36, 91-102. The N-n-alkylpyridinium salts
4-7 (FIG. 3) were obtained via n-alkylation of pyridine with

the appropriate n-alkyl halide. The conformationally

one, and the anti-free base was prepared from 5-aza-1-tetral

45

50

one. N,N'-Dodecanediyl-bis-nicotinium dibromide, 18 (FIG.

4), was prepared by dissolving S-(—)-nicotine in glacial acetic
acid, stirring the mixture for ?ve minutes and then adding
dibromododecane. The solution was stirred under re?ux for

three days, the solvent was evaporated under reduced pres

55

curves to obtain EC5O and IC5O values.
60

[3H]-Nicotine ((>t4[32* Subtype) and [3H]-Methyllycac
onitine (00* Subtype) Binding Assays.
Whole brain, excluding cortex and cerebellum, was

with chloroform. After ?ltration, the ?ltrate was dried over

anhydrous MgSO4 and removal of solvent afforded the bis

homogenized in 20 ml of ice-cold buffer, containing (in mM):
2 HEPES, 11.8 NaCl, 0.48 KCl, 0.25 CaCl2 and 0.12 MgSO4,
pH 7.5. Homogenate was centrifuged (25,000 g, 15 minutes,

nicotinium salt, 18. N,N'-Dodecanediyl-bis-pyridinium
dibromide, 19 (FIG. 4) was prepared by reacting an excess of
pyridine with dibromododecane for 24 hours at 65° C. in the
absence of solvent. The resulting solid was collected by ?l
tration, dissolved in water, and the aqueous solution washed

“release,” is the more correct terminology because the neu
rotransmitter measured is the net result of release and

reuptake. Data were analyzed by weighted, least squares
regression analysis of the sigmoidal concentration-effect

sure, and the resulting residue was treated with an aqueous

saturated solution of NaHCO3. The resulting mixture was

then extracted with diethyl ether (3x50 mL), and then with
chloroform (3x50 mL). The aqueous layer was collected and
lyophilized for 24 hours, and the resulting solid was triturated

the tissue at the time of sample collection (de?ned as frac
tional release). The sum of all the increases in [3H]-dopamine
fractional release resulting from either exposure to analog or
nicotine equaled “total over?ow”. “Over?ow,” rather than

65

40 C.). Pellets were resuspended in 20 ml of buffer and incu
bated at 37° C., for ten minutes, cooled to 4° C. and centri

fuged (25,000 g, 15 minutes, 4° C.). Pellets were resuspended

US 8,546,415 B2
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and centrifuged using the same conditions. Final pellets were

TABLE 5

stored in assay buffer, containing (in mM): 20 HEPES, 118
NaCl, 4.8 KCl, 2.5 CaCl2, and 1.2 MgSO4) pH 7.5 at —700 C.

Inhibitory activity of simple N-n-alkylpyridinium analogs at native
nAChRs.

Upon use, ?nal pellets were resuspended in ~20 ml assay

buffer. Samples (250 pl) contained 100-140 ug of membrane
protein, 3 nM [3H]-nicotine or 3 nM [3H]-methyllycac

onitine, and analog (0.1 uM-l mM) in assay buffer containing
50 mM Tris. Control was in the absence of analog. In [3H]
nicotine and [3H]-methyllycaconitine binding assays, non
speci?c binding was determined in the presence of 10 uM

Compound

Nicotine-evoked
[3H]DA Over?ow
1050 uM"

[3H]Nicotine
Binding
K,- M!’

[3H]MLA
Binding
K,- M!’

NDPI

0.13 (0.02-0.87)

17 (14-20)

na

NDDPI

0.26 (0.02-4.23)

na

na

NPDPB

0.32 (0.11-0.87)

38 (28-51)

na

NEcPB

0.12 (0.01-2.38)

na

na

nicotine, and 10 uM methylycaconitine, respectively. Incu
“Values are means of ?ve to six independent experiments, 95% con?dence interval is given

bations proceeded for 60 minutes at room temperature using
96-well plates and were terminated by harvesting on Uni?l

in parentheses.
alues are means of four independent experiments, 95% con?dence interval is given in
parentheses (na = not active.)

ter-96 GF/B ?lter plates presoaked in 0.5% polyethylen
imine, using a Packard FilterMate harvester.
After washing ?ve times with 350 pl ice-cold assay buffer,

Example 36

?lter plates were dried (60 minutes, 490 C.), bottom-sealed,
and ?lled with Packard’s MicroScint 20 cocktail (40 ul/well).
After 60 minutes, ?lter plates were top-sealed, and radioac
tivity determined using a Packard TopCount. Protein concen

20

trations were determined using bovine serum albumin as the

standard.

Blood-Brain Barrier Choline Transporter Af?nity Assays.

25

Quaternary ammonium analogs were evaluated for their

ability to inhibit [3 H] -choline uptake into brain providing an
indication of the ability of these analogs to interact with the
choline transporter. These assays were conducted using the in
situ rat brain perfusion method of Takasato, et al., Am. J.

30

Physiol. 1984, 247, 484, as modi?ed by Allen and Smith, J.
Neurochem, 2001, 76, 1032. Inhibition coef?cients (Ki, con

The nAChR receptor properties of some conformationally
restricted analogs of the above N-n-alkylnicotinium com
pounds are shown in Table 6. These analogs were designed to
assess the rotameric preference about the C3-C2‘ bond of
NONI and NDNI for interaction with nAChR subtypes. Two

classes of bridged nicotinium analogs, representing extreme
rotameric conformations (i.e. syn- and anti-rotamers, FIG. 3)
were examined. Interestingly, these conformationally
restrained analogs lacked al?nity for (x4[32* and (>t7*
nAChRs, as determined from [3H]-nicotine and [3H]-meth
yllycaconitine binding assays. In addition, with the exception
of BCDD, these analogs potently and selectively inhibited
nicotine-evoked [3H]-dopamine release (IC5O values 30-660

nM), although no clearly de?ned structure-activity trends

centration of analog inhibiting 50% of [3H]-choline uptake

could be determined. These analogs may be interacting with

into brain) were determined using a single inhibitor concen

multiple nAChR subtypes mediating nicotine-evoked
dopamine release. Alternatively the lack of structure-activity

tration as described by Smith, et al., .1. Neurochem, 1987, 49,
1651. K- values were compared by ANOVA followed by

35

relationships within this group may be due to the fact that
these molecules are racemic in nature. It is conceivable that

Bonferoni’s multiple comparisons test to determine if an

analog inhibits [3H]-choline uptake.
40

TABLE 4

the optical isomers of each compound may exhibit different
al?nities at the nAChR subtypes examined, thus confounding
the structural analysis.
TABLE 6

Evaluation of N-n-alkylnicotinium analogs at native nAChRs.

Compound
NONI
NDNI

NDDNI

Nicotine-evoked

[3H]Nicotine

[3H]MLA

[3H]DA Over?ow

Binding

Binding

1050 M“

K,- pMb

K,- uMb

0.62 (0.20-1.9)

20 (15-25)

12 (9.2-16)

na

0.09 (0.08-0.11)

na

0.009 (0.003-0.03)

0.14 (0.11-0.17)

na

Inhibitory activity of simple N-n-alkylpyridinium analogs at native
Nicotine-evoked

Compound
50

“Values are means of three to ten independent experiments, 95% con?dence interval is given
in parentheses (na = not active).
“Values are means of four to ten independent experiments, 95% con?dence interval is given
in parentheses (na = not active).

55

Example 35

[3H]DA Over?ow
IC5O uM“
0.08
0.66
0.58
0.04
0.22
0.04
0.31
0.03
0.04

[3H]Nicotine
Bindingl7

[3H]MLA
Bindingl7

(10.04)
(10.03)
(10.55)
(10.02)
(10.15)
(10.02)
(10.01)
(10.03)
(10.03)

na
na
na
na
na
na
na
na
na

na
na
na
na
na
na
na
na
na

na

na

na

“Values are means of six to eight independent experiments for the DA release assay, standard
error is given in parentheses (na = not active).

etermined at a single 10 M concentration in four independent experiments.

60

Example 37

respectively; Table 5). These compounds also lack al?nity for
(>t7* nAChRs. These data demonstrate the importance of the

3-(2'-pyrrolidino) moiety in the N-n-alkylnicotinium series of
compounds for potent inhibition of nAChR subtypes mediat
ing nicotine-evoked dopamine release.

ACO
ACN
ACD
ACU
ACDD
BCO
BCN
BCD
BCU
BCDD

Simple N-n-alkylpyridiniums, with alkyl chain lengths
ranging from C1 to C20, exhibit moderate to low af?nity for
nAChR subtypes mediating nicotine-evoked DA release and
for (x4[32* nAChRs (IC5O:90-530 nM and Ki:9-44 uM,

nAChRs

45

The bis-aZaaromatic quaternary ammonium analogs:
65

N,N'-dodecanediyl-bis-nicotinium dibromide (18, FIG. 4),
and N,N'-dodecanediyl-bis-pyridinium dibromide (19, FIG.
4), were synthesiZed and evaluated for their inhibitory prop

US 8,546,415 B2
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erties at nAChR subtypes (Table 7). C 1 2 analogs Were studied,
based on our ?ndings that the C12 analog (NDDNI) in the

uptake Was 1.5910.14><10_3 ml/s/g, calculated from the slope

N-n-alkylnicotinium series Was the most potent as an inhibi

uptake time of 45 seconds Was chosen as Within the linear

tor of the nAChR subtype mediating nicotine-evoked [3H]

portion of the brain uptake curve in order to evaluate [3H]
NONI brain uptake in the presence of unlabeled NONI. Unla
beled NONI (250 uM) in the perfusion ?uid resulted in 46%

of the compound accumulating in brain versus time. An

dopamine over?ow. These compounds Were not potent or

selective for the subtype mediating nicotine-evoked dopam
ine release.

inhibition of [3H]-NONI brain uptake, suggesting saturable
kinetic parameters associated With NONI transport into brain.

The ability of choline to inhibit [3H]-NONI uptake into

TABLE 7

brain and [3 H] -NONI distribution parameters Were also deter

Inhibitory activity of N,N'—bis—azaaromatic quaternary ammonium

mined. The permeability-surface area product (PA; ml/s/g)

C‘7 analogs bNDDB and bPDDB at native nAChRs.

Nicotine-evoked

[3H]Nicotine

[3H]MLA

for [3H]-NONI With no inhibitors present Was 1.6410.37><
10'3 ml/ s/ g, determined as a single time point PA value. If

[3H]DA Over?ow

Binding

Binding

r050 uM"

K,- M!’

K,- uMb

NONI is transported in total, or in part, by the blood-brain

bNDDB

0.17 (10.13)

1.95 (10.19)

na

perfusion ?uid should reduce brain uptake of [3H]-NONI.

bPDDB

1.00 (10.38)

9.15 (10.17)

33 (14.6)

When 500 uM choline Was added to the perfusion ?uid the PA

Compound

barrier choline transporter, then addition of choline to the

“Values are means of four to six experiments, standard error is given in parentheses.
bValues are means of three to four experiments, standard error is given in parentheses (na =

not active).

20

for [3H]-NONI decreased ~25% to 1.2410.5><10_3 ml/s/g. A
higher concentration (5 mM) of choline further reduced the
uptake of [3H]-NONI to 7.5513.30><104 ml/s/g, Which Was
<50% of the uptake in the absence of choline. These results
demonstrate that a signi?cant component of NONI uptake

Example 38

occurs via the blood-brain barrier choline transporter.

Analog Af?nity for, and Transport by, the
Blood-Brain Barrier Choline Transporter

N-n-Alkylpicolinium analogs shoWn in FIG. 5 Were pre

Several N-n-alkylnicotinium analogs have been shoWn to
have good a?inity for the blood-brain barrier choline trans

pared by reacting 3-picoline With the appropriate n-alkyl
iodide utiliZing conditions described in Crooks, et al., Drug

porter. Speci?cally, NONI, inhibits [3H]-choline uptake
(Table 8) With an apparent K- value of 49 uM (124 uM). The
C 1 analog, NMNI, shoWs loW af?nity for the transporter, With
an apparent K- value of greater than 1000 uM. The C1O analog,
NDNI, inhibits [3H]-choline uptake into brain With an appar
ent Kl. value of 27 uM (12 uM), similar to NONI and choline.
The C4 analog, NBNI, has an apparent K- value of 7771588

Example 40

25

30

35

Dev. Res. 1995, 36, 91. The N,N'-alkyl-bis-picolinium ana
logs shoWn in FIG. 5 Were prepared by reacting an excess of
3-picoline With a variety of diiodo- or dibromoalkanes for 24
hours in the absence of solvent. The resulting solid Was col
lected by ?ltration, dissolved in Water and the aqueous solu
tion Was Washed With diethyl ether (3x50 mL). The aqueous
solution Was then lyophiliZed to afford either a solid or vis

uM. These results demonstrate that increasing the length of
the N-n-alkyl chain in these N-n-alkylnicotinium analogs
facilitates transporter binding, and thus, enhances brain
uptake via the blood-brain barrier choline transporter.

cous hygroscopic oil. All compounds Were characterized by
1H and 13 C NMR spectroscopy, mass spectroscopy and

elemental analysis.
40

Biological Assays:

TABLE 8

Male Sprague-DaWley rats (225-250 g) Were obtained
from Harlan Industries (Indianapolis, Ind.) and housed tWo

Af?nity of N-n-alkylcholine analogs and N-n-alkylnicotinium analogs

per cage With free access to food and Water in the Division of

for the blood brain barrier choline transporter.
45

Concentration

Compound

11M”

Lab Animal Resources in the College of Pharmacy at the
University of Kentucky. All experiments Were carried out in
accordance With the 1996 NIH Guide for the Care and Use of

Ki 11M”

Laboratory Animals and Were approved by the Institutional
N-n-Octylcholine
N-n-Hexylcholine
N-n-Octylpyridinium iodide

10
10
250

1.7 (10.3)
2.2 (10.1)
32 (122)

NBNI
NONI
NDNI

250
250
250

777 (1590)
49 (124)
27 (10.1)

Animal Care and Use Committee at the University of Ken

tucky.
50

[3H]DA release assays Were performed according to pre
viously published methods With minor modi?cations. Striatal
slices (500 um, 4-6 mg) Were incubated for 30 minutes in

Krebs’ buffer (in mM: 118 NaCl, 4.7 KCl, 1.2 MgCl2, 1

“Values are means of three to ?ve independent experiments, standard error is given in

parentheses.
In vitro therapeutic index (ICSO cytotoxicity/ICSO complement inhibition)

NaH2PO4, 1.3 CaCl2, 11.1 glucose, 25 NaHCO3, 0.11
55

L-ascorbic acid and 0.004 disodium EDTA, pH 7.4, saturated
With 95% O2/5% CO2) in a metabolic shaker at 34° C. Slices

Example 39

Were incubated With 0.1 uM (?nal concentration) [3 H] DA

[3H]-NONI Brain Uptake

during the latter 30 minutes of the 60-minute incubation
period. Each slice Was transferred to a glass superfusion
60

Were performed to verify that this compound gains access to
brain via the blood-brain barrier choline transporter. Thus,
brain distribution parameters of [3H]-NONI Were deter

mined. Uptake of [3H]-NONI (1 uCi/ml) into rat brain Was
evaluated from 0-60 seconds in the absence of unlabeled

NONI. The transfer coe?icient value (Kl-n) for [3H]-NONI

chamber maintained at 34° C. and superfused (1 ml/min) With

Krebs’ buffer containing nomifensine (10 uM) and pargyline
(10 uM) to inhibit [3H]DA reuptake and metabolism, respec

Considering the above Kl. value for NONI, experiments

tively, after release into the extracellular space, ensuring that

[3H]over?oW primarily represents [3H]DA. Sample collec
65

tion (5-minute; 5 ml) began after 60 minutes of superfusion.
The ability of N-n-alkylpicolinium and N,N'-alkyl-bis-pi
colinium analogs to evoke [3 H] DA release (i.e., exhibit intrin

US 8,546,415 B2
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sic activity) and to inhibit nicotine-evoked [3H]DA release

TABLE 9-continued

(i.e., act as nAChR antagonists) were determined. To estab

lish that these analogs act as nAChR antagonists, by de?ni

Inhibitory activity of N-n-alkylpicolinium iodide analogs at

tion, inhibition of the response to nicotine must be observed at
analog concentrations that do not evoke a response. Thus, the

native nAChRs.

ability of these analogs to elicit intrinsic activity (evoke [3 H]
DA over?ow) was determined. At the end of the experiment,
each slice was solubiliZed and [3H]content of the tissue deter
mined. Release during each minute was normaliZed for total

Compound
NUPiI

NDDPiI

[3 H] content of the slice. Analog-induced intrinsic activity and
inhibitory activity were determined using slices from the

20

release and reuptake. Typically, data were analyZed by
weighted, least squares regression analysis of sigmoidal con
centration-effect curves to obtain EC5O and IC5O values.

Interaction of the analogs with nAChR subtypes probed by
25

to rat brain membranes was determined to assess nAChR

MLA binding assays were performed using whole brain,
30

Na

Na

Na

Na

Table 9 shows the inhibitory activity of the N-n-alkylpi
colinium analogs with carbon chain lengths of CS-Cl2 in the
nicotine-evoked [3H]DA over?ow assay and in the [3H]nico
tine and [3H]MLA binding assays. This series of analogs was
relatively selective for the nAChR subtype(s) mediating nico
tine-evoked [3H]DA over?ow, in that, these analogs did not
inhibit binding of either [3H]nicotine and [3 H] MLA to rat
brain membranes, indicating low a?inity for or no interaction
with 0462* and 00* nAChRs.
In the nicotine-evoked [3H]DA over?ow assay, NDDPiI at

analogs demonstrated no intrinsic activity up to 1.0 uM. As
the carbon chain length was increased the inhibitory potency

at nAChRs mediating nicotine-evoked [3 H] DA over?ow

NaCl, 0.48 KCl, 0.25 CaCl2, and 0.12 MgSO4, pH 7.5).
Homogenates were centrifuged (25,000 g, 15 minutes, 40 C.).

increased with a rank order of NDDPiI>NDPiI>NOPiI (Table
9). The most potent analog in the series was NDDPiI

Pellets were resuspended in 20 ml of buffer and incubated at

37° C., for 10 minutes, cooled to 40 C. and centrifuged (25,
000 g, 15 minutes, 40 C.). Pellets were resuspended and
centrifuged again using the same conditions. Final pellets

nd

0.03 (10.02)

concentrations of 21.0 uM evoked [3H]DA over?ow, and
thus, exhibited intrinsic activity; whereas the C8 and C10

subtype selectivity of the analogs. [3H]Nicotine and [3 H]
excluding cortex and cerebellum. Whole brain was homog
eniZed in 20 ml of ice-cold buffer (in mM: 2 HEPES, 11.8

[3H]MLA
Binding
K,- M!’

(na = not active).

in [3 H]DA fractional release resulting from either exposure to
analog or nicotine equaled “total [H]DA over?ow”. “Over
?ow,” rather than “release,” is the more correct terminology

[3H]nicotine binding (0462*) and [3H]MLA binding (00*)

[3H]Nicotine
Binding
K,- M!’

“Values are means of three to ?ve independent experiments, standard error is given in
parenthesis (nd = not determined).
bValues are means of four independent experiments, standard error is given in parentheses

same rat (repeated-measures design).
Fractional release was calculated by dividing the total tri
tium collected in each sample by the total tritium in the tissue
at the time of sample collection. The sum of all the increases

because the neurotransmitter measured is the net result of

Nicotine-evoked
[3H]DA Over?ow
1c50 11M”

35

(IC5O:30 nM). Furthermore, NDDPiI inhibited nicotine
evoked [3H] DA over?ow by 63%, indicating that this analog
may interact with a single subtype of nAChR that mediates
this effect of nicotine.

were stored at —70° C. in assay buffer (in mM: 20 HEPES, 1 18

NaCl, 4.8 KCl, 2.5 CaCl2, and 1.2 MgSO4, pH 7.5). Upon use,

Table 10 illustrates the ability of a series of N,N'-bis-alky

?nal pellets were resuspended in ~20 ml assay buffer.

lpicolinium analogs with carbon chain lengths of C6-Cl2 to
inhibit nicotine-evoked [3H]DA over?ow and the binding of
[3H]nicotine and [3H]MLA to rat brain membranes. None of

Samples (250 pl) contained 100-140 pg of membrane protein,

40

3 nM [3H]nicotine or 3 nM [3H]MLA, and a range of con

centrations (0.1 uM-l mM) of analog in assay buffer contain

the analogs in this series inhibited either [3H]nicotine or

ing 50 mM Tris. Control was in the absence of analog. In

[3H]nicotine and [3 H] MLA binding assays, nonspeci?c bind
ing was determined in the presence of 10 uM nicotine and 10

45

Furthermore, none of the N,N'-bis-alkylpicolinium ana

uM MLA, respectively. Incubation proceeded for 60 minutes

logs in this series evoked [3H] DA over?ow, and thus, they did
not exhibit intrinsic activity at subtypes mediating nicotine

at room temperature using 96-well plates and was terminated

by harvesting on Uni?lter-96 GF/B ?lter plates, presoaked in
0.5% polyethylenimine, using a Packard FiterMate harvester.
After washing 5>< with 350 pl ice-cold assay buffer, ?lter
plates were dried (60 minutes, 49° C.), bottom-sealed, and
?lled with Packard’s MicroScint 20 cocktail (40 ul/well).
After 60 minutes, ?lter plates were top-sealed, and radioac
tivity determined. Protein concentration was determined
using BSA as the standard. The results are shown in Table 9.

[3H]MLA binding with high a?inity, indicating no a?inity at
00,* nAChRs and only low a?inity at 0462* nAChRs.
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evoked DA release. The most active analogs in this series are
those with the longer n-alkyl chain length and with an even
number of carbon atoms (Table 10). bPiDDB (the C 1 2 analog)
was the most potent (ICSOIS nM) inhibitor of the nAChR

subtype mediating nicotine-evoked [3H] DA over?ow.
55

bPiDDB is also selective for the nAChR subtype mediating
nicotine-evoked [3 H] DA over?ow, since it has low or no

a?inity for the 0462* and 00* nAChR subtypes (Table 10).
TABLE 9
Inhibitory activity of N-n-alkylpicoliniurn iodide analogs at
native nAChRs.

Compound
NOPiI
NNPiI
NDPiI

60

Nicotine-evoked

[3H]Nicotine

[3H]MLA

[3H]DA Over?ow

Binding

Binding

1c50 11M”

K,- M!’

K,- 0M1’

1.0 (10.09)
nd
0.3 (10.05)

Na
62 (117)
26 (13.6)

Na
Na
Na

Thus, bPiDDB is a selective inhibitor of the nAChR subtype
that mediates nicotine-evoked [3H]DA over?ow. bPiDDB is
approximately 320-fold more potent than DHBE in inhibiting
nicotine-evoked [3 H] DA over?ow. bPiDDB and the other
analogs in this series inhibited [3H]DA over?ow by a maxi
mum of 60%, similar to the maximum inhibition observed for

conotoxin-MII, suggesting that this small synthetic molecule
(bPiDDB) and the neurotoxic Conus peptide of higher
molecular weight may be acting at the same nAChR subtype
to inhibit nicotine-evoked DA release.

US 8,546,415 B2
30
wherein:
Rings 1 and 2 are pyridinium;

TABLE 10
Inhibitory activity of N,N'—bis—picolinium salts at native

R2, R3, R4, R5, R6 are each independently selected from
hydrogen; alkyl; and substituted alkyl;
R1 is selected from alkyl, substituted alkyl, cycloalkyl,
substituted cycloalkyl, alkenyl, substituted alkenyl,
alkynyl, substituted alkynyl, aryl, substituted aryl,
arylalkyl, substituted arylalkyl, arylalkenyl, substi
tuted arylalkenyl, arylalkynyl, substituted arylalky

nAChRs.

Compound
bPiHxI
bPiOI
bPiNB
bPiDI
bPiUB
bPiDDB

Nicotine-evoked

[3H]Nicotine

[3H]MLA

[3H]DA Over?ow
10,0 11M”

Binding
K,- M!’

Binding
K,- 6M1’

Na
Na
80 (217)
Na
69 (229)
49 (217)

Na
Na
Na
Na
Na
Na

1.66
0.01
1.52
0.03
1.61
0.005

(20.85)
(20.009)
(20.34)
(20.01)
(21.08)
(20.003)

nyl, heterocyclic, substituted heterocyclic, alkoxy,
alkylamine, thioalkyl; and
X is selected from Cl, Br, I, HSO4, 1/2SO2, CH3SO3,
p-TsO, CF3SO3 and any ion that completes the salt
form of the nicotine antagonist; and enantomers, dias

“Values are means of four to six independent experiments, standard error is given in
arenthesis.

tereomers and racemic mixes thereof,
wherein the nicotine antagonist binds to nAChR and inhib

gValues are means of four independent experiments, standard error is given in parentheses
(na = not active).

its release of dopamine.
The N,N'-dodecyl-bis-aZaaromatic analogs (i.e. the C 1 2

analogs) were tested and compared for their inhibitory activ
ity. The compounds tested included the dibromide salts of the
C 1 2 analogs of bis-nicotinium (bNDDB), bis-pyridinium (bP

DDB),

bis-picolinium

(bPiDDB),

2. The method of claim 1 wherein the dopamine mediated
disease state is selected from the group consisting of myas
20

thenia gravis, Parkinson’s disease, Alzheimer’s disease,

schizophrenia, eating disorders, and drug addiction.
3. The method of claim 2 wherein said drug addiction is to
a drug selected from the group consisting of nicotinic ago

bis-quinolinium

(bQDDB), and bis-isoquinolinium (bIQDDB). The results

nists, cocaine, amphetamines, caffeine, phencyclidine, opi

are shown in Table 11.
25

ates, barbituates, benZodiaZepines, cannabinoids, hallucino

TABLE 11

gens and alcohol.
4. The method of claim 2 wherein the composition is

Inhibitorv activity of the C‘? N N'—bis-AZaaromatic analogs.

administered orally, transdermally, transnasally, rectally, sub
linguinally, subdermally, intraocularly or via smokeless inha

Nicotine
evoked

30

Over?ow
ICSO (11M)

Uptake
K.- (HM)

Binding
K.- (PM)

Binding
K.- (11M)

0.04 2 0.02
1.00 2 0.38
0.005 2 0.003

43.2 214.9
>100
>100

1.95 2 0.19
9.15 2 0.17
48.6 2 17.2

>100
33 2 4.6
>100

bQDDB

0.0212001

3.86 20.22

>100

1.612021

bIQDDB

0.007 2 0.003

0.27 2 0.07

6.10 2 0.73

2.21 2 0.25

Compound
bNDDB
bPDDB
bPiDDB

lation.
5. A method of treating drug addiction in a patient com
prising administering to the patient an effective amount of a

composition comprising at least one nicotine antagonist hav
ing the formula
35

bPiDDB has 4-5 orders of magnitude higher af?nity for the nAChR subtype mediating
nicotine-evoked [3H] DA over?ow compared to its af?.nity at both 014 [542* and 017* nAChRs. 40
Thus, based on the preclinical data, by inhibiting dopamine release bPiDDB and related
analogs should diminish the rewarding effects produced by nicotine self-administration and
serve as tobacco use cessation agents.

What is claimed is:

1. A method of treating a dopamine mediated disease state
comprising administering to an individual in need thereof an
effective amount of a composition comprising at least one

45

nicotine antagonist having the formula
50
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wherein:
Rings 1 and 2 are pyridinium;
R2, R3 , R4, R5 , R6 are each independently selected from

hydrogen; alkyl and substituted alkyl;
R1 is selected from alkyl, substituted alkyl, cycloalkyl,
substituted cycloalkyl, alkenyl, substituted alkenyl,
60

alkynyl, substituted alkynyl, aryl, substituted aryl,
arylalkyl, substituted arylalkyl, arylalkenyl, substi
tuted arylalkenyl, arylalkynyl, substituted arylalky

nyl, heterocyclic, substituted heterocyclic, alkoxy,
alkylamine, thioalkyl; and
65

X is selected from Cl, Br, I, HSO4, 1/2SO2, CH3SO3,
p-TsO, CF3SO3 and any ion that completes the salt
form of the nicotine antagonist; and enantomers, dias
tereomers and racemic mixes thereof,

